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Development and characterization of a 
transdermal formula for an extract of the 
medicinal plant Harpagophytum procumbens 
(Burch.) DC. ex Meisn.
 
ABSTRACT 
 
The skin is the largest and most readily accessible organ of the body. The stratum corneum 
forms the outermost layer of the skin, which functions as a barrier to the external 
environment and regulates the passage of molecules across the skin. Drug delivery across 
the skin offers advantages over other routes of administration, bypassing the hepatic first 
pass metabolism, maintaining therapeutically effective drug levels, and improved patient 
compliance. Currently, there is a strong trend in the use of plant materials and extracts for 
medicinal purposes. Devil’s Claw (Harpagophytum procumbens) is a medicinal plant located 
in many regions throughout Southern and South Africa. It is used for its anti-inflammatory 
and analgesic properties with the harpagoside and harpagide components present reported 
to be responsible for these properties. Its activity has been reported to be as a result of the 
direct and indirect inhibition of Cyclooxygenase- 2 enzyme (COX-2).  
Efforts to improve the permeation of synthetic conventional compounds are constantly 
investigated, and great improvements of these formulations have led to very effective 
formulation of transdermal dosage forms such as anti-inflammatory drugs. The same should 
be possible for medicinal plants.  
 Optimal permeation across the skin requires a drug to possess lipophilic as well as 
hydrophilic properties. Research suggests that a drug should have an aqueous solubility of 
more than 1 mg/ml and an octanol-water partition coefficient (log P) between 1 and 2 to 
optimally penetrate the skin (higher values indicating increased lipophilicity). Compounds not 
possessing these characteristics may be facilitated across the skin by the introduction of 
permeation enhancers in the formulation that include Azone® and sodium dodecyl sulphate 
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(SDS). 
The main aims of this study were to make an extract of Harpagophytum procumbens and to 
determine the direct COX-2 inhibition activity of this extract and further to formulate this 
extract into a pharmaceutical gel, with permeation enhancers that maintains its COX-2 
enzyme inhibition qualities after transdermal penetration. 
The analytical techniques verified the existence of a harpagide and harpagoside 
components in the crude Harpagophytum procumbens extract and they were quantified in 
the extract at 3% and 1% respectively. 
COX-2 inhibition by the Harpagophytum procumbens extract was determined by a direct 
enzyme inhibition study and quantified by means of measuring the production of the product 
formed by the enzyme over a time interval in the presence of excess enzyme substrate. 
Crude Harpagophytum procumbens extract demonstrated a greater COX-2 enzyme 
inhibition than pure harpagide and harpagoside individually and combined. This indicated 
the existence of compounds in the extract contributing to this synergistic effect. This was 
reflected in the IC50 values indicating that the Harpagophytum procumbens crude extract 
had the lowest IC50 values concentration when compared to the harpagide and harpagoside. 
Octanol-PBS partition coefficient (log D) experiments were performed with various 
permeation enhancers and gels with varying combinations in order to determine the 
changing partitioning properties of harpagide and harpagoside. 
The octanol-PBS partition coefficient (log D) experiments indicated that harpagoside had a 
higher log D value than harpagide. 
  The addition of permeation enhancers resulted in changes in the partition co-efficient of the 
marker compounds. The permeation enhancer, Azone®, resulted in the smallest reduction of 
Log D for harpagoside and the largest increase in Log D compared to other permeation 
enhancers tested for harpagide. 
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When the 2 marker compounds were formulated into different gel formulations 
(hydroxypropyl cellulose, Carbopol Ultrez 21® and Pluronic®), harpagide had the largest 
increase in Log D with the Carbopol Ultrez 21® gel. Harpagoside had the largest increase in 
the hydroxypropyl cellulose gel. 
Combinations of gel formulations with permeation enhancers were tested. The 2 best 
performing permeation enhancers in hydroxypropyl cellulose gel were SDS and Azone®. 
These compounds resulted in the largest increase in lipophilic partitioning for harpagide and 
harpagoside compound and higher values were achieved with SDS. 
Following the partition co-efficient determination, permeation studies with synthetic 
membranes were performed with the selected enhancer/gel formulations using Franz 
diffusional cells. 
 The permeation (flux) across the hydrophobic synthetic membrane (Sil-Tec®) indicated flux 
of 27.1µg.cm-2.h-1 for harpagoside and 156.0 µg.cm-2.h-1 for harpagide in the hydroxypropyl 
cellulose gel. Incorporation of Azone® in the hydroxypropyl cellulose formulation resulted in 
an enhancement ratio (ER) of 14 for harpagoside. The hydroxypropyl cellulose gel with the 
permeation enhancers (Azone® and SDS) did not result in enhancement of permeation of 
the harpagide.  
 Permeation of harpagoside and harpagide across the hydrophilic synthetic membrane 
(Tuffyrn®) yielded flux values of 537.1 µg.cm-2.h-1 and 101.1µg.cm-2.h-1 respectively in the 
Gel formulations. The Gel formulation containing Azone® and SDS, resulted in similar flux 
across this membrane compared to the formulation consisting of the Gel only, with the 
Azone® containing formulation resulting in lower flux for harpagide.  
 
Transdermal permeation was measured through excised female human abdominal skin 
using Franz diffusion cells. 
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Flux values for harpagoside and harpagide were 18.4 µg.cm-2.h-1 and 5.0 µg.cm-2.h-1 
respectively when the crude extract was in the hydroxypropyl cellulose gel tested on human 
skin.  Formulation of the crude extract in hydroxypropyl cellulose gel including Azone® and 
SDS permeation enhancers resulted in enhancement of 8 and 7 respectively for harpagide. 
Azone® increased the flux of harpagoside 14 times in the same hydroxypropyl cellulose gel 
formulation. The SDS had very little effect. The enhancement ratios achieved with the 
human skin was higher than that of the synthetic membranes. 
 
Post transdermal COX-2 inhibition activity studies were performed with the Azone® Gel 
formulation after it permeated across the human skin membrane to determine to what extent 
inhibitory activity of the crude extract was maintained. The crude drug retained its direct 
COX-2 inhibitory activity after permeation across the human skin with 77% inhibitory activity. 
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THESIS OVERVIEW 
 
 
Standardization – Identification and extraction of Harpagophytum procumbens 
extract. 
Identification and purity testing of marker compounds in crude plant extract. 
Standardization of extraction technique. 
 Chapter Four 
Determination of direct Cyclooxygenase- 2 (COX-2) inhibition. 
After the marker compounds were indentified and quantified in the crude extract these 
marker compounds (harpagide and harpagoside) were tested to determine their ability to 
directly inhibit COX-2  enzymes. These studies were also performed with the 
Harpagophytum procumbens crude extract. 
 Chapter Five  
Physiochemical properties and solubility. 
Physiochemical properties of compounds play a fundamental role in the ability of 
compounds to permeate across membranes. It was therefore necessary to determine 
what the physiochemical parameters of the marker compunds were such as solubilty, 
partition co-efficient and  molecular weight. 
 Chapter Six 
 
 
 
 
xxi 
 
 
Gel Formulation 
In order to perform permeation studies (synthetic and human membranes) various gel 
formulations  in combination with permeation enhancers were tested for their influence on 
altering the partition co-efficient to achieve values close to the suggested range of log D 
between 1-2. The best performing gel and enhancers were selected for synthetic 
membrane permeation experiments. 
 Chapter Six  
Synthetic membranes 
This was performed in order to determine the release of harpagoside and harpagide from 
gel formulations (with and without enhancers). This indicated the effect that the 
permeation enhancers, Azone® and SDS, had on the permeation pattern of harpagoside 
and harpagide. 
 Chapter Seven 
Transdermal permeation 
The selected gel formulation with permeation enhancers were tested for its  transdermal 
permeation ability. The gel formulation and enhancer combination with the highest flux 
were selected for post COX-2 enzyme inhibition activity. 
 Chapter Seven 
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Post-permeation COX-2 enzyme inhibition activity. 
This was performed to determine to what extent the the crude Harpagophytum 
procumbens plant extract retained its ability to directly inhibit the COX-2 enzyme after 
permeation across the human skin.  
 Chapter Eight 
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CHAPTER ONE:  Introduction and problem statement. 
 
1.1  INTRODUCTION 
 
Devil’s Claw (Harpagophytum procumbens) is a medicinal plant geographically located in 
many regions throughout Southern Africa. Its typical habitat is open savannahs and arid 
regions. It has been used for a range of medicinal properties and historically been used to 
treat various ailments. The root of the plant has been used mainly for its anti-inflammatory, 
antipyretic, osteoarthritic pain and analgesic properties (Van Wyk et al., 1997). Devil’s Claw 
contains iridiode glycosides, sugars, triterpenoids, sterols, carbohydrates and waxes (Wichtl, 
2004). The harpagosides (iridiode glycosides) is believed to be the main compound 
imparting medicinal properties (Van Wyk et al., 1997). Harpagophytum procumbens extract 
as well as some of its components such as harpagoside and harpagide has demonstrated 
anti-inflammatory properties by indirect inhibition Cyclooxygenase -2 enzyme (COX-2) 
(Zhang et al., 2011; Gyurkovska et al., 2011; Fiebich et al., 2001). COX-2 catalyzes 
reactions that produce prostaglandins, which are involved in inflammation processes. 
Traditional dosage forms of Harpagophytum procumbens include infusions and decoctions, 
which are taken orally as well as ointments, which are applied topically (Van Wyk et al., 
1997). More conventional dosage forms include tablets, teas, tinctures, liquid extracts and 
creams. These crude forms usually contain between 1-2% of the harpagoside extract 
(Wichtl, 2004).  
Standardization is important to ensure consistency of active ingredients in all batches of 
crude drugs or extracts and ultimately the dosage forms. Quality and purity assays can be 
performed by thin layer chromatography (TLC), High-pressure liquid chromatography 
(HPLC), and Gas liquid chromatography (GC) techniques. 
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Efforts to improve the dermal permeation of pharmacologically active compounds are 
constantly investigated, and great improvements of formulations have led to very effective 
formulation of transdermal dosage forms such as those containing anti-inflammatory drugs. 
Ibuprofen and diclofenac sodium have successfully been formulated into transdermal 
dosage forms. The same is possible for medicinal plants and the formulation process should 
be facilitated through the development of a standardized membrane permeation model. 
 
Transdermal drug delivery has advantages over other conventional delivery routes such as 
ease of administration, bypassing first pass hepatic metabolism, avoidance of variable rates 
of absorption and metabolism as well as the elimination of gastrointestinal irritation (El-
Kattan et al., 2000; Naik et al., 2000; Godwin et al., 1997). Due to these advantages there is 
a trend in reformulating existing formulation into transdermal drug delivery systems.  
The stratum corneum (SC) forms the outermost layer of the skin and is a multilamellar lipid 
milieu with protein-filled coenocytes, which augment membrane integrity, and increases 
membrane tortuosity. This intrinsic tortuosity coupled with the lipophilic nature of the SC 
ensures a barrier against the entry of drug molecules with the exception of highly lipophilic 
substances (Kalia and Guy, 2001). When a drug is released from a transdermal device it 
should diffuse through the SC, as well as the hydrophilic viable epidermis and dermal layer 
(Barry, 2007). An ideal drug candidate for systemic transdermal drug delivery should have 
sufficient lipophilicity to penetrate the SC, as well as sufficient hydrophobicity to enable the 
second partitioning step into the viable epidermis and eventually the systemic circulation 
(Kalia and Guy, 2001). 
For most drug compounds the rate-limiting step for drug transport across the skin is transit 
across the stratum corneum (Nolan et al., 2003). There are various techniques to measure 
drug diffusion across the skin, including human and animal in vitro studies.  
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Transdermal membrane models such as synthetic polymeric membranes e.g. Carbosil, 
Silistic, and Sil- Tec® (Feldstein et al., 1998; Megrab et al., 1995; Schwarb et al., 1999) may 
be used to measure in vitro drug diffusion. The advantage of these models over skin is their 
availability, uniformity, tensile strength and chemical purity. It aims to mimic the permeation 
activity of the skin (in vitro and in vivo) and usually is the first step in determining drug 
permeation across the SC. Membrane choice is important when studying trans membrane 
movement of drugs as with Devils Claw, which contain numerous compounds with different 
lipophilic and hydrophilic characteristics. 
Human skin (normally difficult to obtain) may be obtained from cadavers or surgical and 
cosmetic procedures. Variables such as age, gender, anatomical site and general health of 
the donor, lead to variability in drug permeation (Feldstein et al., 1998). This is the preferred 
membrane to use in permeation studies. 
When formulating a topical transdermal drug delivery dosage form, the main complication is 
usually enhancement and controlling the rate of permeation. The incorporation of 
permeation enhancers resulting in manipulation of the partition coefficient may be used to 
overcome these complications (Rowat et al., 2006; Masson et al.,, 1999; Megrab et al.,, 
1995).  
Medicinal plant contain a complexity of compounds with varying physical and 
physiochemical properties many of which are unknown of which Harpagophytum 
procumbens is no exception. The formulation of a topical transdermal dosage form 
consisting of crude plant extracts such as Harpagophytum procumbens extract would 
require consideration as to how these compounds could affect the physical and physio 
chemical properties of the dosage form. These properties could influence the release profile 
of compounds in the crude extract and permeation across the human skin. 
If successful transdermal permeation of crude medicinal plant components is achieved in a 
formulated topical dosage form, it would be essential to establish whether the activity of 
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these crude plant extracts has been maintained after the permeation process. In the case of 
Harpagophytum procumbens crude extract, it would mean determining if this medicinal plant 
can directly inhibit COX-2 enzyme activity and then establish to what extent the crude 
extract has maintained the COX -2 inhibition ability after transdermal permeation. 
 
This could be the first step towards the successful creation of a therapeutically effective 
transdermal preparation of Harpagophytum procumbens. 
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1.2  AIM AND OBJECTIVES  
 
To prepare and standardize an extract of Harpagophytum procumbens and to formulate the 
extract into a transdermal pharmaceutical preparation. This preparation should have the 
ability to effectively permeate the skin without losing its COX-2 inhibition activity. The 
preparation should have the potential to be utilized as an effective natural anti-inflammatory 
transdermal dosage form. 
 
In order to meet these goals the following objectives were set: 
o Develop a standardized extraction method to produce a constant crude 
Harpagophytum procumbens extract. 
o Perform quality, purity and identity tests by means of Thin layer 
Chromatography (TLC) and High Pressure Liquid Chromatography 
(HPLC) on the Harpagophytum procumbens crude extract. 
o Develop a method and experimentally measure the direct COX–2 enzyme 
inhibitory activity of the crude extract of Harpagophytum procumbens, 
harpagoside and harpagide glycosides. 
o Experimentally perform partition coefficient studies with selected 
permeation enhancers and gel formulation combinations of the 
Harpagophytum procumbens crude extract containing harpagoside and 
harpagide. 
o To formulate the crude extract into a transdermal topical gel preparation. 
o Experimentally determine the permeation (flux) of harpagoside and 
harpagide compounds from the crude extract in gel formulations across 
synthetic membranes. 
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o Experimentally determine the permeation (flux) of harpagoside and 
harpagide compounds from the crude extract in gel formulations across 
the human skin (transdermal). 
o Experimentally determine the permeation flux of harpagoside and 
harpagide with various permeation enhancers. 
o Determine the relationship between the flux values of the synthetic 
membrane and human skin. 
o Determine the extent to which the gel formulation retained the ability to 
directly inhibit COX–2 enzyme after transdermal permeation. 
 
The COX-2 percentage inhibition, partition co-efficient and flux values data generated were 
evaluated statistically using one way analysis of variance (ANOVA). Tukey's multiple 
comparisons test was applied (if ANOVA indicated significant difference) to find the source 
of possible differences between the various data obtained. Differences were considered 
statistically significant for a P-value ≤0.05. Analysis of data was performed using GraphPad 
Prism® 5.  
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CHAPTER TWO:  Plant Medicine 
2.1  Introduction to plant medicine 
 
 Plants have always formed the basis of traditional medicine and continue to reveal new 
remedies.  The first records of medicinal properties of plants were from Mesopotamia (2600 
BC); among the substances used were oils of Cedrus species (Cedar), Glycyrrhiza glabra 
(licorice), Commiphora species (Myrrh) and Papaver somniferum (Poppy juice) all of which 
are still used today for ailments ranging from coughs, infections to inflammation (Gurib-
Fakim, 2006). 
Traditional African medicine is the oldest and possibly the most diverse of all traditional 
medicines systems due to its rich cultural and biodiversity (Gurib-Fakim, 2006). Well known 
African medicinal plants include Agathosma betulina (Buchu), Acacia Senegal (Gum Arabic), 
Aspalanthus linearis (Rooibos tea), Artemesia afra (African wormwood) and Harpagophytum 
procumbens (Devil’s claw).  
Modern allopathic medicine has its roots in ancient medicine, and it is likely that new 
remedies will be discovered and commercialized following leads provided by traditional 
knowledge.  It is estimated that 80% of the world’s population, mostly developing countries, 
are dependent on traditional medicines for primary healthcare and that 25% of all prescribed 
medicines contain some ingredients derived from plants (Mander and Le Brenton, 2006). 
In the past couple of decades there has once again been a shift in the use of traditional plant 
medicines, sales figures in the USA increasing each year over the last 5 years (Blumenthal 
et al., 2011) suggesting that it may be an attractive area of research. Newer technologies in 
equipment, separation techniques and structure elucidations have resulted in making it 
easier to determine the mechanisms of activity of plant compounds with better 
understanding their role in disease states and discovery of new chemical entities (Mukherjee 
and Houghton, 2009).  
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What is also evident is that newer versions of monographs and pharmacopeias such as 
British pharmacopeia, European pharmacopeia and European Scientific Cooperative on 
Phytotherapy (ESCOP) monographs have included monographs for more plant compounds 
with more sophisticated methods for identification, purity and assay procedures. 
The interest in plant based medicine is apparent in that globally, there were more than 90 
registered clinical trails involving various plant compounds between 2001 and 2007 for the 
treatment of conditions such as central nervous system (CNS) related diseases, cancer 
therapy and inflammatory conditions (Saklani and Kutty, 2008). 
Medicinal plant products can be categorized as follows (Mander and Le Brenton, 2006): 
Herbal remedies – these are processed plant based medicinal products whose therapeutic 
claims do not have formal legal recognition. They are based on traditional therapies, which 
may be single products to multi-species complex blends. 
Crude plant based traditional medicine - frequently little processing is required before 
administration, and at most, the plant material is ground or boiled and sometimes mixed with 
other plant components. These medicines have a long history of use and their healing 
powers are closely linked with cultural beliefs. 
Plant derived allopathic medicine – these products have a degree of legal recognition and 
are sometimes referred to as phytochemicals. They usually consist of single plant species, 
which are incorporated into conventional pharmaceutical techniques and traded on the basis 
of proven medical efficacy.  
Unlike formulated conventional active components, which are mostly synthesized and 
usually free from contamination and batch-to-batch variation, plants components are 
naturally sourced compounds. This affects extract composition, potency and the extent of 
unwanted compounds such as contaminants (Mukherjee and Houghton, 2009). 
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The traditional modes of administration for medicinal plant components are usually the oral 
route for decoctions, infusions/teas and tinctures; the nasal route for snuffing; and topical 
route from cream, ointment and gels (Van Wyk and Wink, 2004).  
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 2.2  Medicinal crude plant extracts 
Medicinal plants usually contain a vast variety of compounds, which may act individually, 
through polyvalence or synergistically for its desired therapeutic effect (Houghton, 2009). 
Traditional plant medicines are usually administered as a crude extract as opposed to 
individual isolated components (Van Wyk and Wink, 2004; Mills and Bone, 2000). This is in 
line with traditional therapy aiming to restore body function through a more holistic approach, 
which include whole extracts or mixtures of plant substances. There may be other 
advantages of using the crude extract compared to using individual components. The co-
effectors may impact the solubility, stability or half-life of the active compound and the 
presence of unknown components in the crude extract may play a part in the overall effects 
of crude extracts which may offer better stability of various active compounds (Williamson, 
2001; Houghton, 2009).  
2.2.1  Synergy  
 
Synergy may be understood as an effect seen by a combination of substances being greater 
than would have been expected from a consideration of individual contributions (Williamson, 
2001). Many effective phytomedicines are present in the form of whole extracts and it 
suggested that it is as a result of synergistic interactions between the components of the 
individual or a mixture of plant extracts. Synergy is not unique in plant extracts or between 
various plant species as it has been demonstrated to be present in various conventional 
medicines and between conventional and plant medicines (Pelizzaro-Rocha et al., 2010; 
Veras 2011; Nitteranon et al., 2011; Fiebich et al., 2011).  
The isobole method (Berenbaum, 1989) is the most appropriate method for describing 
synergism in plant material as it is independent of the mechanism of action and makes no 
assumptions about the behavior of each component and it is appropriate for multi-
component mixtures. 
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This is demonstrated in figure 2.1 (Williamson, 2001) where the combination of compounds 
(da and db) is represented on the curve, the axis being the dose-axes of these individual 
compounds (Da and Db). If there is no interaction between these compounds then a straight 
isobole is the resultant (dashed line).  If there were synergistic activity present the 
combination of the components required would be less than for the sum of the individual 
compounds and a concave curve is a result (Fig. 2.1.b) the converse of that would be 
antagonism (Fig. 2.1.a). 
 Figure 2.1 Synergism and antagonism of crude plant extracts. 
 
Until recently, there were not many clinical studies proving the concept of synergy in plant 
material, which was often dismissed by skeptics.  This view was supported by the fact that 
the mechanisms of actions of the activity of many medicinal plants cannot be explained. 
However, the clinical and in vitro effects of synergy in plants components are reported more 
frequently. Gyurkovska et al. (2011) tested the inhibition of COX-2 expression by crude 
extracts and components of Harpagophytum procumbens. It yielded strong inhibitory effects 
and suggested that this high activity is as a result of synergistic activity between the various 
components of the crude extract. Nitteranon et al., (2011) demonstrated the synergistic 
effects of the components of the extract Morinda Citrifolia where low concentrations of 
quercetin and scopoletin resulted in suppression of inducible nitric oxide synthase (iNOS) 
and COX-2 expression which are components in inflammatory responses. Synergy has also 
been reported with other plant extracts such as Ginkgo biloba, Cannabis sativa, Croton 
gratissimus and Lippia sidoides (Williamson, 2001; van Vuuren and Viljoen 2008; Veras et 
al., 2011). 
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2.2.2  Polyvalence 
Polyvalence can be defined as the range of biological activities that an extract may exhibit 
which contribute to the overall effect observed clinically or in vivo (Houghton, 2009). In 
certain instances as with Harpagophytum procumbens, the crude extract may contain a 
range of active compounds which all contribute to its efficacy. This may not necessarily 
indicate synergy (Williamson, 2001). What should be considered is that the additive effects 
of the individual components of a crude extract contribute to the total effects produced by the 
crude extract. This is represented by Mulyaningsih et al., (2010) investigating the synergistic 
properties of the terpenoids aromadendrene and 1,8 –cineole of Eucalyptus globulus who 
indicated that activity of the eucalyptus extract components could be the result of additive 
effects of its other components rather than synergy. 
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2.3  Formulation of plant extracts into conventional 
  dosage forms. 
 
The shift to renewed interest through a more structured approach in identification and 
regulation of plant medicines serves as an opportunity to develop a good connection 
between crude extracts of traditional plant medicine with the standardized and regulated 
practices used in the evaluation and formulation of allopathic medicines. 
 
Although traditional medicine has been used for many centuries, scientific research and 
development in phytotherapy have suffered through lack of patent protection and the relative 
small scale of the industries involved when compared to conventional pharmaceutical 
industries (Mukherjee, 2009).  
Formulation processes with crude extracts become more difficult due to the need to consider 
more than one active compound unlike conventional allopathic formulations, which in most 
cases, only consist of one synthesized active compound. In plant extracts there are several 
known and unknown compounds such as active compounds, waxes and sugars present. 
This could affect factors such as solubility, partitioning coefficient and pH of the formulation 
making formulation of plant extracts into conventional dosage forms such as gels more 
complicated. 
In recent years, more traditional plant compounds (crude extracts and isolated compounds) 
have been formulated into more conventional dosages forms. These include tablets, 
capsules and topical dosage forms. The benefit with this approach is that the formulation 
and qualitative tests generated could be useful for improved quality control, delivery and 
shelf-life (Vyas et al., 2011; Georgetti et al., 2008; Endale et al., 2005). Casagrande et al., 
(2007) formulated the plant derived flavonoid, quercetin, into a topical dosage form indicated 
that quercetin was released from the dosage form and displayed activity after release from 
the topical dosage form. Soybean extract has also been formulated into topical dosage 
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forms consisting of emulsifying and gelling agents; these topical preparations demonstrated 
physiochemical stability and anti-oxidant properties. (Georgetti et al., 2008; Georgetti et al., 
2006). 
2.4  Current therapy for inflammatory conditions. 
 
Medicinal treatment for inflammatory conditions such as acute and chronic arthritic pain 
includes the administration of corticosteroids and anti-inflammatory agents. The anti-
inflammatory agents comprise the non-steroidal anti-inflammatory drugs (NSAIDs) and the 
selective COX-2 inhibitors drugs. 
2.4.1  Non-steroidal anti-inflammatory drugs (NSAIDs) 
 
Most NSAIDs inhibit both COX-1 and COX-2 when administered at effective doses in the 
reduction of inflammation and pain with the majority displaying COX-1 selectivity (Motilva et 
al., 2005; Hawkey, 1999). Despite their toxicity, NSAIDs is a commonly prescribed group of 
drugs; this is a reflection of the widespread prevalence and chronic nature of arthritic and 
musculoskeletal disease (Hawkey, 1999). However the main limitation of the use of NSAIDs 
is gastrointestinal injury (Laine, 2002). 
2.4.2  Selective COX-2 inhibitors 
 
The selective COX-2 inhibitors have been developed for a better gastrointestinal safety 
profile (Motilva et al., 2005). COX-2 selective inhibitors, such as celecoxib and refocoxib 
demonstrate the same anti-inflammatory, antipyretic and analgesic effects as the non-
selective NSAIDs but may result in 50% to 60% lower gastrointestinal side effects (Laine, 
2002). However, the selective COX-2 anti-inflammatory compounds do produce side effects, 
most notably the increased cardiovascular risks which have resulted in the commercially 
available drug Vioxx® (refocoxib) being removed from the market (Laine et al., 2008; Baron 
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et al., 2008; Juni et al., 2004). The consequence of this is that it has likely resulted in 
continued use of the NSAIDs in spite of their gastrointestinal side effects. 
Medicinal plant compounds could be considered a possible alternative to NSAIDS and 
selective COX-2 inhibitors in the treatment of various inflammatory conditions.  The 
medicinal plant Harpagophytum procumbens extract with its iridiode glycosides harpagoside 
and harpagide has proven anti-inflammatory activity. 
2.2.3  Iridiodes 
 
They are a subclass of the monoterpenes (10 carbon structure), which includes more than 
200 structures, which are distributed in the plant families, Apocynaceae, Gentiannaceae, 
Lamiaceae, Loganiacceae, Menyanthacceae, Plantaginacceae, Rubiaceae, 
Scrophulariacceae, Valerianacceae and Verbanacceae (Van Wyk and Wink, 2004). Various 
iridiode glycosides including harpagoside and harpagide iridiodes are present in different 
plant species such as Harpagophytum procumbens (Pedaliaceae), Scrophularia ningpoensis 
(Scrophulariacceae) and Scrophularia scorodonia (Ebrahim and Uebel, 2011; Benito et al., 
2000; Li et al., 1999). The iridiodes have anti-inflammatory properties and are used as 
analgesics and anti-rheumatics.  The lactone ring of the iridiode glycoside generates a 
reactive aldehyde function, which can form covalent bonds with amino groups of proteins. 
This action could explain the anti-inflammatory properties of iridiode compounds where the 
alkylation could lead to the inhibition of cyclooxygenase interfering with inflammation 
promoters such as prostaglandins (Van Wyk and Wink, 2004). 
2.5  Harpagophytum procumbens (Devil’s Claw) 
 
The typical habitat of Devil’s Claw (Harpagophytum procumbens) is open savannahs and 
arid regions geographically located in many regions throughout Southern Africa that include 
South Africa, Namibia Zambia and Zimbabwe. 
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2.5.1  Macroscopic description 
 
 The plant consists of long flat branches (up to 1,5 meters) spread on the ground, lobed 
leaves, reddish violet flowers covered with hook-shaped projections and active components 
are suggested to be contained in the secondary storage roots (figure 2.2 and figure 2.3). 
Figure 2.2 Harpagophytum procumbens plant. 
    
   Figure 2.3 Harpagophytum procumbens root. 
                                     
2.5.2  Uses 
 
Traditionally in South Africa, it is used in digestive disorders, anti-inflammatory conditions, 
analgesia and the treatment of allergies (Wichtl, 2004). 
2.5.3  Chemical composition 
 
Harpagophytum procumbens contains sugars; phytosterols; phenolic acid; triterpenes; 
sterols; fats and iridiode glycosides (Wichtl, 2004). The iridiode glycosides consist of 
 
 
 
 
17 
 
harpagoside, harpagide, procumbide and procumboside (Bruneton, 1999). Harpagoside, the 
main compound in the fresh and dried root and harpagide (possibly a degradation product of 
harpagoside and procumbide) (figure 2.4) are believed to be the main components to have 
medicinal properties (Van Wyk et al.,, 1997). 
2.5.4  Harpagoside 
 
The iridiode glycoside harpagoside is the main compound in the fresh and dried root (Van 
Wyk et al.,, 1997) According to the European Pharmacopoeia, the crude extract should not 
contain less than 1.2% harpagoside. It has a molecular weight of 494 Dalton and is soluble 
in acetonitrile, ethanol and water. It exhibits a maxima UV wavelength absorbance at 280 
nm ± 2 nm. 
 Figure 2.4: Chemical structures of harpagoside, harpagide and procumbide. 
 
 
2.5.5  Harpagide 
 
The iridiode glycoside harpagide is a possible degradation product of harpagoside with a 
molecular weight of 364 Dalton, soluble in water and methanol. This compound does not 
possess absorbance spectra in the UV absorbance range.  
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2.5.6  Preparations 
 
Harpagophytum procumbens is most commonly administered orally as a tea (infusion) and 
more recently as dry extract preparations in the form of capsule, powder and tablet (Van 
Wyk, 1997). The tea is made by pouring 300ml of water over 4.5 gram of finely cut root or 
coarse powder, steeped for 8 hours at room temperature and then strained. The teas are 
taken three times per day.  In the case of the dry extract preparation it usually contains 
between 200 mg to 480 mg per gram of preparation. 
2.5.7  Clinical studies 
 
The clinical efficacy of Harpagophytum procumbens for inflammatory conditions has been 
reported. These clinical tests predominantly use the whole Harpagophytum procumbens 
extract, mainly investigating its effects on osteoarthritis and lower back pain (Gagnier et al.,, 
2004; Chrubasik et al., 2002). A study conducted by Chantre et al., (2000) indicated that 
Harpadol capsules which is a formulation containing 435 mg of Harpagophytum procumbens 
extract is comparable to 100 mg/ml diacerein in efficacy for the treatment of osteoarthritis. 
The study also revealed that patients using Harpadol required less frequent usage of the 
NSAID, diclofenac. 
Gagnier et al., (2004) suggests that the Harpagophytum procumbens extracts should 
contain between 50mg and 100mg of harpagoside to have moderate to higher efficacy for 
clinical conditions such as osteoarthritis and chronic lower back pain with the nature of the 
solvent used in the extraction procedure also contributing to the concentration required. 
Variances exist with respect to extent of the clinical efficacy of Harpagophytum procumbens 
extracts. This may be related to different clinical assessment criteria used and type of extract 
used in the studies (McGregor et al., 2005; Gagnier et al., 2004). 
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2.5.8  Animal studies 
 
Studies involving COX-2 inhibition by Harpagophytum procumbens extract in animals 
indicate a reduction in pain and inflammation during experimental test procedures. This is 
demonstrated by Lanhers et al., 1992 who reported that the crude extract produced 
significant dose dependent anti-inflammatory effects in response to acute inflammatory 
induction (carrageenan-induced rat paw oedema test).  Similarly, Anderson et al., 2004 
reported the anti-inflammatory effects with extracts of Harpagophytum procumbens in rats 
with Freund's adjuvant induced arthritis in the acute and chronic phase of inflammation by 
measuring reduced oedema. However, animal studies tend to indicate that isolated 
components such as harpagoside do not demonstrate anti-inflammatory properties 
(McGregor et al., 2005; Lanhers et al., 1992). 
2.5.9  In Vitro studies 
2.5.9.1  Cyclooxygenase 2 
 
Cyclooxygenase is a membrane bound enzyme responsible for the oxidation of arachadonic 
acid to prostaglandin and the subsequent reduction of prostaglandin G2 to prostaglandin H2 
(PGH2). Cyclooxygenase enzymes are expressed in at least two main isoforms, 
Cyclooxygenase-1 (COX-1) and Cylclooxygenase-2 (COX-2). These two isoforms display 
about 50% homology and have similar catalytic activity but they are physiologically distinct 
(Eldeen and Van Staden, 2008). The COX-1 is a constitutive enzyme present in most cells, 
which act as homeostatic regulators, involved with functions such as gastric cytoprotection 
and platelet aggregation (Rang et al., 2003; Ouellet, 2001). 
COX-2, an inducible enzyme, is not normally present in cells but it is strongly induced in 
inflammatory cells – in response to tissue injury or pro-inflammatory agents, with the primary 
inflammatory cytokines, interleukin and tumour necrosis factor (TNF)-α playing an important 
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role (Motilva et al., 2005; Rang et al., 2003). COX-2 is the principal isoform that participates 
in inflammation and its induction is responsible for the production of prostaglandins at the 
site of inflammation (Murias et al., 2004). 
The process of producing anti-inflammatory effects by compounds could involve various 
mechanisms. These include the measurement of the inhibition of enzyme activity through 
reduced enzyme expression (McGregor et al., 2005); measurement of direct inhibition of the 
enzyme (Corazzi et al., 2005) or measuring other biochemical activities due to reduced 
cyclooxygenase enzyme output (Kundu et al., 2005). 
The anti-inflammatory properties of Harpagophytum procumbens extract and some of its 
components have been attributed to the inhibition of the enzyme activity related to COX-1 
(Jang et al., 2003) and COX-2 (Ouitas and Heard, 2008), the latter being more frequently 
investigated. 
As a result of varying methodologies for assessing COX-2 activity, the literature indicates 
varying degrees of efficacy of Harpagophytum procumbens and its components in 
possessing COX-2 inhibitory effects. A study by Zhang et al., (2011) investigating the effect 
of harpagoside and harpagide on the inhibition of the COX-2 enzyme by measuring 
prostaglandin concentration revealed that these two compounds did not have inhibitory 
activity at concentrations of up to 100µM. However, Abdelouahab and Heard, 2008 reported 
that the harpagide component had pro-inflammatory activity as a result of an increase in 
COX-2 activity. 
The study by Gyurkovska et al., 2011 investigated the COX-2 inhibitory activity of 
Harpagophytum procumbens crude extract and various isolated components through 
various mechanisms of action. They demonstrated a decrease in the concentration of nitric 
oxide, which is a powerful pro-inflammatory mediator with the crude extract as well as its 
individual components. The same study also performed tests to observe the effect 
compounds would have on the TNF-α and IL-6 pro- inflammatory mediator concentration. 
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The results indicate that the crude extract displayed COX-2 inhibitory effects but 
harpagoside and harpagide did not produce significant COX-2 inhibitory effects.  The 
inhibitory effect of the crude extract is similar to a study by Fiebich et al., (2001) who 
indicated a decrease in LPS induced TNF-α and IL-6 release. Conversely, the Fiebich study 
did produce inhibitory action attributed to harpagoside. 
 
When observing the different methods and techniques used to evaluate the COX-2 inhibition 
and anti-inflammatory effects of Harpagophytum procumbens it does indicate that generally, 
the crude extracts display anti-inflammatory characteristics and that opposing results with 
respect to  efficacy is mainly attributed to the individual components of the crude 
Harpagophytum procumbens extract such as harpagoside. This may be related to 
differences in the method of inhibition assessment and plant extract composition (McGregor 
et al., 2005; Loew et al., 2001). The Harpagophytum procumbens extract with all its 
constituents seems to be the most effective in the inhibition of COX-2 compared to its 
individual constituents, which may be related to synergy (Abdelouahab and Heard, 2008.) 
The studies mentioned above demonstrate the COX-2 inhibition by Harpagophytum 
procumbens extract through the assessment of indirect COX-2 enzyme inhibition rather than 
direct inhibition of the COX-2 enzyme. 
The present study will demonstrate the direct inhibition of COX-2 enzyme (in contrast to 
others which focus on indirect inhibition) by an extract of Harpagophytum procumbens as 
well as harpagoside and harpagide. DuP-697 was used as the reference inhibitor.  
2.5.9.2  DuP-697 
 
DuP-697 [5-bromo-2- (4-flourophenyl)-3-(4-(methylsulfonyl)-thiophene)] is a member of the 
diaryl heterocyclic group of selective COX- 2 inhibitors, which includes MK-966 recoxib and 
celocoxib (Burdan et al., 2003). Dup-697 is a selective, time dependent and essentially 
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irreversible COX-2 inhibitor (Pinto et al., 1996). It has greater inhibition over COX-2 than 
COX-1 enzymes (50 times). It is soluble in organic solvents such as ethanol, DMSO and 
DMF. DuP-697 is not used clinically due to its long plasma half-life of 242 hours in humans 
(Pinto et al., 1996). It is, however, used in laboratory experimental work as a reference for 
COX-2 inhibitory studies as it demonstrates significant COX-2 inhibition (Copeland et al., 
1994). 
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CHAPTER THREE: Transdermal Drug Permeation 
 
3.1  Introduction  
 
 
The skin offers an excellent barrier to the external environment therefore the rational for 
using the transdermal route of drug delivery needs to be carefully considered. In instances 
where the most convenient drug delivery routes such as the oral route is not viable for drug 
administration then alternatives must be sought. The intravenous route may be considered 
as an option as it has advantages of bypassing gastrointestinal and hepatic metabolism but 
it is an invasive and apprehensive method of drug delivery. Further, most anatomical orifices 
have been investigated for the ability to serve as a route for drug administration. 
Nevertheless, the transdermal route of drug administration offers advantages as a route of 
delivery in addition to bypassing gastrointestinal and hepatic metabolism (Naik et al., 2000). 
The skin has been regarded as a favourable route for the administration of compounds with 
patient compliance and the ease of administration making it an appealing route for delivery 
(El-Kattan et al., 2000). The main advantages of the transdermal drug delivery over other 
conventional delivery modes such as oral administration are bypassing first pass hepatic 
and intestinal metabolism, avoidance of variable rates of absorption and metabolism as well 
as the elimination of gastrointestinal irritation as a result of various compounds in dosage 
forms (Godwin et al., 1997). 
The skin is the largest organ of the body; it covers an area over about 2 m2 and weighs 
about between 4.5 and 5.0 kg with the thickness ranging from 0.5mm to 4mm depending on 
the location on the body (Wickett and Visscher, 2006; Tortora and Gabowski, 1993). 
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Structurally, the skin consists of an outer portion, the epidermis, which is connected to an 
inner thicker connective tissue, the dermis. Beneath the dermis is the hypodermis, which 
consists of areolar and adipose tissue. (Tortora and Gabowski, 1993) 
The skin serves as a two way barrier where it controls the loss of water, electrolytes and 
other body constituents as well as preventing entry of unwanted solutes from the 
environment (Lane and Mclean 2008; Hadgraft 2001). This formidable barrier by function 
therefore restricts the permeation of many compounds; this contributes to the limitation of 
the transdermal delivery as a route of administration.  
The choice of compound used in transdermal delivery is determined by a number of factors, 
which include physiochemical properties such a lipophilicity, solubility, molecular weight and 
interactions with membranes (Naik et al., 2000; Malan et al., 2002; Kalia and Guy 2001). 
Topical drug delivery targets five main groups, namely the skin surface, horny layer, viable 
epidermis and upper dermis, skin glands and systemic circulation. An ideal compound for 
transdermal drug delivery would have sufficient lipophilicity to partition in the stratum 
corneum and also have good aqueous solubility allowing it to partition into the viable dermis, 
epidermis and systemic circulation (Kalia and Guy, 2001). 
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3.2  The skin structure 
 
The cross section of the skin reveals four layers, namely the non-viable epidermis stratum 
corneum, viable epidermis, dermis and subcutaneous layer. 
3.2.1  Stratum corneum 
 
The stratum corneum is thought to be the main barrier to skin penetration and is comprised 
of 20 to 25 layers of flat dead cells surrounded by an intercellular matrix of lipids and 
aqueous layers (Barry, 2001; Barbato et al., 1998; Tortora and Gabowski, 1993). It is mainly 
a hydrophobic layer made up of coenocytes, which are embedded, in continuous 
intercellular lipids. The corneocytes occur in lipid lamellar layers, which may be described as 
having a brick wall formation with the corneocytes being the bricks and the intercellular lipids 
representing the wall (Bouwstra and Ponec, 2006). The tough structure of corneocytes 
provides a form of mechanical support for the intercellular lipid lamellae (Lee et al., 2008).  
The uptake of penetrants into the stratum corneum and its passive diffusion are thought to 
be the rate-limiting step in transdermal penetration (Kalia and Guy, 2001; Barbato et al., 
1998).  
3.2.2  Viable epidermis 
 
The viable epidermis is found between the stratum corneum and the dermis. The epidermis 
is about 50-100  m thick and is a dynamic, constantly self-renewing tissue where cells lost 
at the stratum corneum is balanced by cell growth in the lower basal epidermis layer 
(Bouwstra and Ponec, 2006). It consists of various layers, namely, (from the inside to the 
outside) stratum basale, stratum spinosum and the stratum granulsum (Wickett and 
Visscher, 2006). The predominant cell type in the epidermis is the keratinocyte. They exist 
from the stratum basale to the stratum granulosum at which they transform into the stratum 
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corneum (Wickett and Visscher, 2006). The viable dermis is a more aqueous soluble layer 
than the stratum corneum (Naik et al., 2000). This could be related to its higher water 
content (Morganti et al., 2001). 
3.2.3  Dermis and Hypodermis 
 
The dermis is rich in blood vessels, nerve endings and lymphatic vessels with an extensive 
network, which connects to the systemic circulation where the lymphatic vessel has the 
function of draining excess extracellular fluid and clearing antigenic material (Murthy and 
Shivakumar, 2010). The hypodermis is attached to underlying organs such as bone and 
muscle and is the deepest layer of the skin, which consists of the subcutaneous tissue filled 
with fat cells, macrophages and fibroblasts (Murthy and Shivakumar, 2010; Tortora and 
Gabowski, 1993). 
3.2.4  Skin appendages 
 
In addition to the different layers, the skin consists of sweat glands, hair follicles and 
sebaceous glands. The sweat glands exists in two forms, the larger apocrine glands which 
are exclusively associated in the groin and axillae, and the smaller eccrine glands which is a 
simple coiled structure located in the reticular dermis with an opening directly onto the 
dermis (Bristow and Turner, 2002). The follicular area account for 0.1% and eccrine 10-3% of 
the total surface area of the skin (Hadgraft, 2001).  
3.3  Percutaneous absorption 
 
Percutaneous absorption is a passive process (Hadgraft, 2001) and may be described as 
the uptake of a compound into systemic circulation after dermal application. The process 
may be described as follows (Kalia and Guy, 2001; Flynn and Stewart, 1988): 
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 Partitioning to the outermost layer of the skin, the stratum corneum 
 Diffusion through the stratum corneum, mainly via the intercellular pathway 
 Partitioning from the stratum corneum into the aqueous viable dermis 
 Diffusion through the viable epidermis into the upper dermis 
 Uptake into the local capillary network to systemic circulation 
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3.4  Routes of transdermal delivery 
 
When active molecules come into contact with the surface of the skin they are able to 
penetrate via three potential pathways. This may be through the sebaceous and the sweat 
glands, the hair follicles (the two are together called the transappendageal route) or directly 
across the stratum corneum (figure 3.1) (Benson, 2005). 
 
Figure 3.1 Routes of transdermal delivery. 
 
 Penetration across the stratum corneum involves two potential pathways for the absorption 
of penetrants, the transcellular route (across corneocytes and the lipid matrix) and the 
intercellular route (via the lipid domains between the corneocytes (Suhonen et al., 1999). 
The intercellular route is the primary route of permeation. 
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Figure 3.2 Absorption across the stratum corneum. 
 
3.4.1  Transcellular and Intercellular pathway 
 
Compounds in the transcellular pathway pass directly though the hydrated keratin 
corneocyte layer as seen in figure 3.2 (Barry, 2001). The intercellular route of penetration is 
reported to be the primary means of permeation across the stratum corneum (Kalia and 
Guy, 2001; Bach and Lippold, 1998).  It is a longer and more tortuous route across the 
corneum stratum when compared to the transcellular route. The diffusional pathway is 
therefore longer than the simple path length of the thickness of the stratum corneum and has 
been estimated to be as long as 500µm. This route contains structured lipids and a diffusing 
molecule has to cross lipophilic and hydrophilic domains before reaching the junction 
between the stratum corneum and viable epidermis (Hadgraft, 2004). 
3.4.2  Transappendageal route 
 
Under normal conditions the appendageal route is not thought to be significant in the 
permeation process, which could be related to the low surface area covered by the 
appendages (Hadgraft, 2001). Sebaceous glands release sebum which creates an 
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environment rich in neutral, non-polar lipids in the region of the hair follicle which may be a 
prerequisite for the follicular uptake of some lipophilic drugs. However, sebum may impede 
the transport of hydrophilic compounds (Meidan et al., 2005).  
3.5  Factors affecting transdermal permeation 
3.5.1  Biological factors 
3.5.1.1  Disease and skin conditions 
 
The skin provides the body with a barrier to the external environment but function 
impairment often arises as a result of disease or from direct damage followed by a breach in 
the stratum corneum, These diseases include ichthyosis, psoriasis, atopic dermatitis as well 
as cuts and abrasions (Rawlings et al., 2008; Barry, 2007; Cork et al., 2006). This 
impairment may be demonstrated by the altered integrity of the stratum corneum and may 
lead to an increase in transepidermal water loss (Rawlings et al., 2008).   
3.5.1.2  Skin age 
 
It is suggested that there is no structural difference in the skin of infants and adults (Barry, 
2007). However, the skin like all organs will undergo morphological and functional 
decrement with increased age which results in the thinning of the epidermis by 10% to 50% 
and the slow replacement of lipids which leads to disturbed barrier function (Zouboulis and 
Makrantonaki, 2011).  
3.5.1.3  Skin hydration 
 
Skin hydration can result in an increase in permeability by causing swelling of the stratum 
corneum though perspiration, water diffusion from underlying epidermal layers or occlusive 
vehicles (Barry, 2007; Wickett and Visscher, 2006). The state of hydration of the stratum 
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corneum is one of the most important factors in the determination of the rate of 
percutaneous absorption of a compound, while the level of hydration is a function of the 
water concentration gradient between the dermis and the surface of the skin (Morganti et al., 
2001).  
3.5.1.4  Skin region 
 
Skin permeability rates vary for specific compounds passing through identical skin sites of 
different healthy subjects and permeability various at various skin sites on the body (Barry, 
2007). Variance may be related to age, gender, race and health (Flynn, 2002). The 
thickness of the skin varies at different sites in the, for example, the feet and hands consist 
of double the epidermis thickness compared to other sites (Draelos, 2006). There is an 
inverse relationship between the diffusion path length and flux of penetrants across 
membranes. It could therefore be expected that a decrease in permeability would exist with 
thicker regions of the stratum corneum. The female abdominal skin is the most commonly 
used region for in vitro human transdermal studies due to it not being as thick (compared to 
other regions) and it’s is availability as a result of cosmetic surgical procedures.  
3.5.1.5  Temperature 
 
The body maintains an isothermal temperature of 37º C. Raised temperature increases 
blood flow through the skin, this could facilitate the removal of compounds from the dermis 
resulting in an increase in the concentration gradient across the skin. This, however, is not 
clinically important (Barry, 2007; Flynn, 2002).  
3.5.1.6  Skin metabolism 
 
The skin consists of various layers, components and appendages; which may contribute to 
the metabolism of compounds permeating through it and affect the bioavailability of topical 
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compounds (Muller et al., 2003). Metabolism is particularly important for compounds 
exhibiting local pharmacological effects (Bando et al., 1997). The exact location in the skin’s 
layers and anatomical distributions of metabolic enzyme systems remain uncertain, although 
the epidermis is considered the main site for metabolic activity (Streinstrasser and Merkle, 
1995). 
 The metabolizing enzymes present in the skin, particularly the viable dermis, may affect the 
absorption of compounds by changing the structure of the compounds and therefore its 
physiochemical properties (Haberland et al., 2006). This could affect the lag time in a 
permeation process (Seko et al., 1999). Bioconversion of lipophilic drugs to a hydrophilic 
form plays an important role in percutaneous permeation (Bando et al., 1997). 
However, skin metabolism is not an important consideration as the skin has much less 
capacity to metabolize compounds than in the hepatic or gastrointestinal region (Flynn and 
Stewart, 1988). 
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3.6  Physiochemical properties 
 
Due to the good barrier properties of the stratum corneum, permeation will be a function of 
the physiological properties of compounds and its role needs to be understood in light of the 
mechanisms of permeation across the stratum corneum (Hadgraft, 2004). The diffusion of 
molecules across a barrier is dependent on its physiochemical properties such as partition 
coefficient, solubility and molecular weight (Salgado et al., 2010). 
3.6.1  Drug Solubility in the stratum corneum 
 
The stratum corneum layer is mainly hydrophobic (Godin and Touitou, 2007). As earlier 
suggested, the permeant should possess both lipophilic and hydrophilic solubilities to allow 
for permeation across the various skin layers. If it were too hydrophilic, the compound would 
not be able to transfer into the stratum corneum and if too lipophilic the compound will have 
a tendency to remain in the stratum corneum (Naik et al., 2000). Therefore, compounds with 
good solubility in oil and water should permeate well with an octanol partition value of 
approximately 1-3 (Hadgraft, 2004). 
3.6.1.1  Aqueous solubility 
 
Pharmacological activity is dependent on the solubilization of a drug substance in 
physiological fluids; therefore, compounds must possess some aqueous solubility for 
absorption and therapeutic response. The pH of a formulation is an important factor to 
consider as it affects the solubility of weakly acidic and basic compounds. pH may be used 
to increase the solubility of ionisable compounds, for compounds without the presence of 
ionisable groups the solubility may be increased by the application of surfactants to aqueous 
solutions.  Aqueous solubility of compounds is also of importance for permeation across the 
skin, with an aqueous solubility of more than 1 mg/ml recommended (Gerber et al., 2006). 
Even though compounds in its ionized form offer better aqueous solubility, it should be noted 
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that increased permeation through the stratum corneum is achieved with compounds 
forming ion pairs of opposite charges to temporarily form neutral compounds (Barry, 2001). 
These compounds dissociate into charged species upon reaching the aqueous epidermis. 
3.6.2  Partition coefficient 
 
If a third substance is added to a system containing 2 immiscible liquids, this substance will 
distribute between the liquid phases until the ratio of its concentration in each phase attains 
a certain value known as the partition coefficient (Berthod and Carda-Broch, 2004). This 
value is a measure of the lipophilicity of compounds, which may be used as a prediction of 
how well it will be able to move across membranes. The experimentally determined partition 
coefficient in aqueous and octanol phases is called log P (n-octanol-water coefficient). In 
most instances, the aqueous phase would be water and the organic phase is n-octanol. n-
Octanol is chosen as the solvent for the organic (oil) phase as it displays properties similar 
to that of biological membranes (Barry, 2007).  
The pathway of a drug permeating through the skin involves permeation through the more 
lipophilic stratum corneum and the viable epidermis, which is mainly hydrophilic before 
reaching the dermis. Therefore, an ideal candidate for permeation should have sufficient 
lipophilicity to partition into the stratum corneum and also adequate hydrophilicity to enable 
partitioning into the viable dermal layer of the skin (Kalia and Guy, 2001).  It is suggested 
that compounds with a high lipophilicity will have difficulty leaving the stratum corneum and 
in contrast, compounds with very high hydrophilicity may have difficulty permeating into this 
layer. Therefore, the recommended Log D (n-octanol-PBS coefficient) for a compound 
considered for transdermal permeation is in the range of 1-3 (Gerber et al., 2006, Hadgraft, 
2004).  
The n-octanol-water partition constant (as referred to as partition co-efficient) has been 
known to be a physical property that correlates best with biological activity. It can be used as 
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a measure of lipophilicity and therefore, suitable for characterizing the interaction between a 
chemical substance and biological systems (Danielson and Zhang 1996). 
3.6.3  Molecular weight and volume 
 
The ability of a drug to pass through a membrane is a function of its size as well as its 
volume where the molecular volume is dependent on weight conformation (Mahato, 2007; 
Malan et al., 2002). Molecules with compact conformation will form a lower molecular 
volume and therefore, a higher diffusivity and permeability (Mahato, 2007). Molecular weight 
of compounds for transdermal permeation should have a molecular weight of under 500 
Dalton as increasing molecular weights cause a rapid decline in absorption of compounds 
(Bos and Meinardi, 2000). 
3.6.4  Diffusion 
 
The main component involved in the permeation of compounds through the skin is simple 
passive diffusion. Fick’s law of diffusion can be used to analyze permeation data and used 
predictively (Yamashita and Hashida 2003). Fick’s first law may be used to describe steady 
state diffusion and may be simplified to (equation 1) (Hadgraft, 2001) 
J= 
    
 
    (1) 
J= flux per unit area 
D= diffusion coefficient in the skin 
∆c= concentration difference across skin 
h= diffusional path length 
K= skin vehicle partition coefficient 
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Under normal circumstances the applied quantity of active compound on the surface of the 
skin (capp) is higher than the concentration under the skin and therefore, equation1 is 
simplified to: 
  J = kp.capp        (2) 
Where kp  is permeability constant. The driving force for diffusion may be considered to be 
the concentration gradient. Fick’s Laws of diffusion demonstrates that the flux (J) should 
increase linearly until capp reaches the solubility limit (equation 2). So any concentration 
above the solubility limit in the same vehicle will result in the same flux value. However, if the 
conditions are such that the compound can be supersaturated and these unstable conditions 
maintained it will result in flux values higher than that in the usual saturated form. Further, in 
some instances the thermodynamic properties of an active compound may change due to 
constituents in the formulation, this may result in different formulations containing the same 
concentration of active compounds having reduced flux values (Hadgraft, 2001). 
Upon application to a membrane, little or no drug penetrates the membrane that it comes 
into contact with the skin in the first moments upon its application (equation 3), this is 
referred to as the lag time (LT) (Yamashita and Hashida 2003): 
  LT =
  
  
          (3) 
LT = Lag time 
L= thickness of the skin (membrane) 
D= diffusion coefficient 
After the first drug compounds permeate the membrane, the flux of the drug increases until it 
reaches a steady state portion represented by the linear segment of a cumulative 
concentration versus time curve. 
 
 
 
 
37 
 
3.6.5  Flux 
 
Flux is the rate of change of the cumulative mass of drug that passes per unit area and time 
through the membrane (Xiong et al., 1996).  Steady state flux (Jss) is determined from Fick’s 
law of diffusion (equation 4): 
Js = dQr/Adt           (4) 
Where Js is the steady state membrane flux, dQr is the change in quantity of material 
passing the membrane into the receptor compartment; A is the active diffusion area and dt is 
the change in time. The steady state flux of the various formulations through the membranes 
is calculated from the slope of the linear portion of the cumulative amount permeated 
through a membrane per unit area versus time (Niazy, 1996) 
3.6.6  Enhancement Factor 
 
In order to express the extent of enhancement of the flux due to the presence of permeation 
enhancers a parameter called the enhancement factor (equation 5) [also known as 
enhancement ratio (ER)] is calculated as follows (Xiong et al., 1996; Diez-Sales et al., 1996): 
   
                 
                    
     (5) 
This is the ratio of flux with the penetration enhancer to the flux without the enhancer. 
3.7  Gels 
3.7.1.   Pluronic® F-127 gel 
 
Pluronic® is a non-ionic surfactant that consists of polyethylene oxide (PEG) and 
polypropylene oxide (PPO) co-polymers. At given concentration it remains as individual 
(non-associated) co-polymers at temperature below the critical micelle temperature (CMT). 
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Above the CMT the molecules become more lipophilic with PPO groups positioned at the 
core of the micelle (Antunes et al., 2011). 
The high solubilizing capacity and its non-toxic properties make it suitable for drug delivery 
(Pisal et al., 2004). It consists by weight of 70% ethylene oxide and 30% propylene oxide 
and is non-toxic (Lee et al., 2004; DiBiase and Rhodes, 1996). Pluronic® F-127 has been 
used with various active compounds as a vehicle in its gel matrix in ear, nasal and 
ophthalmic dosage forms as well as transdermal drug delivery studies (Ma et al., 2008; Lee 
et al., 2004; Pisal et al., 2004; DiBiase and Rhodes, 1996). It has thermo reversible 
properties where an aqueous solution of Pluronic®-127 forms a non-chemically cross-linked 
hydrogel upon warming to ambient temperatures and body temperature (Ma et al., 2008; 
Pisal et al., 2004).  
3.7.2  Carbopol Ultrez 21®  
 
Carbomer resins are allylpentaerythritol-cross linked, acrylic acid-based polymers, which 
have a high molecular weight.  Many types of carbomer resins are available with varying 
degrees of viscosity (Allen, 1998). Carbopol Ultrez 21® polymer performs effectively over a 
wide range of pH range. It may also be used to incorporate substance with high oil content 
and botanical ingredients (Lubrizol, 2008) 
3.7.3  Hydroxypropyl cellulose 
 
Hydroxypropyl cellulose is a thermoplastic polymer, which may be used as thickening agent 
in gels. It is soluble in water and compatible organic solvents such as ethanol and propylene 
glycol (APhA and PSGB, 1986). Janathraprapapa and Stagni (2007) formulated a 
hydroxypropyl cellulose gel for permeation studies consisting of ethanol, propylene glycol 
and meloxicam. This gel formulation successfully incorporated various permeation 
enhancers when used as a topical application for permeation studies.  
 
 
 
 
39 
 
3.8  Permeation enhancers 
 
Permeation enhancers are chemical components of a formulation that facilitate absorption of 
compounds when applied to the surface of the skin. They increase permeation by either 
“pushing” the drug into the skin by the thermodynamic activity of the penetrant being 
increased in the formulation or by pulling” the drug into the skin by permeating the skin and 
increasing the solubility of the penetrant in the skin (Sloan et al., 2006). Penetration 
enhancers should ideally be non-toxic, non-allergic, pharmacologically inert, compatible with 
penetrants and formulation excipients, tasteless odorless, colourless and have good solvent 
properties (Sinha and Maninder 2000). In addition, the permeation enhancer should not 
result in the loss of bodily fluids and electrolytes and the skin should be allowed to regain its 
barrier properties upon the removal of the enhancer (Barry, 2007).  
No permeation enhancer possesses all these properties required for the ideal enhancer; 
also enhancers perform differently based on various physiochemical properties of the 
penetrant. Currently, there is plethora of studies investigating permeation enhancer activity 
and mechanisms, in vivo and in vitro. Thus, there is sufficient data available for the general 
classification of the permeation whether it favors hydrophilic or hydrophobic compounds for 
improved permeation. The mechanism of action of these permeation enhancers may be act 
by one or more mechanisms from the 3 categories below based on the lipid-protein-partition 
concept (Barry, 2001): 
Protein modification - Surfactants that are ionic in nature such as dimethsulphoxide 
(DMSO) are able to interact well with the keratin in corneocytes, which results in dense 
protein structures opening up resulting in them becoming more permeable. These ionic 
surfactants may also modify the peptide/protein material in the bilayer. 
Lipid action - The enhancer disrupts the stratum corneum lipid formation therefore resulting 
in it becoming more permeable. The accelerant molecules move into the lipid bilayer, 
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rotating, vibrating and trans-location. This results in the formation of micro cavities and 
increasing free volume available for drug diffusion. 
Partitioning promotion - Solvents enter the stratum corneum, changes the solution 
properties by altering the chemical environment; this would then result in an increase in the 
partitioning of a second molecule into the horny layer of the skin that may be a penetrant. 
These may also be co-solvents such as water, propylene glycol and ethanol. 
Many permeation enhancers may display more than one of the above-mentioned 
mechanisms. The in-use concentration of permeation enhancers should also be considered 
as a high concentration may reduce activity of the enhancer. Furthermore, these elevated 
concentrations may also have disruptive and irritant properties at elevated concentrations 
(Williams and Barry, 2004; Diez-Sales et al., 1996). 
The stratum corneum is known to offer diffusional resistance and is constituted by complex 
interaction of lipid and proteinatious components, which creates distinct hydrophilic and 
hydrophobic pathways (Walker and Smith, 1996). 
3.8.1  Azone® 
 
Azone® (1-dodecylazacycloheeptan-2-one or laurocapron) was the first molecule specifically 
designed as skin penetration enhancer. It can be considered chemically to be a hybrid of a 
cyclic amide with an alkylsulphoxide group. It is odorless, possesses a smooth yet oily feel 
and is highly lipophilic with a log P value of about 6.2 (Williams and Barry, 2004).  
Azone® appears to perform its activity by the reduction of the diffusional barrier of the 
stratum corneum by inserting itself into structured lipids which are located in the intercellular 
channels resulting in the reduction of the fluidity of the microenvironment of the lipids leading 
to an increase in diffusion (Degim et al., 1999). This compound is soluble in alcohols and 
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propylene glycol and has been reported to have the ability to promote flux of hydrophobic 
and hydrophilic compounds (Williams and Barry, 2004). 
The efficacy of Azone® is concentration dependent with the lower values being favoured 
(Williams and Barry, 2004; Sinha and Kaur, 2000; Degim et al., 1999; Niazy, 1996). Xiong et 
al., (1996) demonstrated that Azone® incorporated into a Carbopol Ultrez 21® gel 
formulation displayed higher permeation of the permeant across the skin with a 5% 
concentration of Azone® compared to a 10% concentration. A high concentration could lead 
to a decrease in the permeation enhancement ratio, which is related to the lipophilicity of the 
penetrant used (Diez-Sales, 1996). 
Azone® is considered to be a good permeation enhancer with studies showing that it has 
higher properties of improving flux across various membrane types including the human 
stratum corneum when compared to other enhancer types (Chatterjee et al., 1997; Xiong et 
al., 1996). Xiong et al., (1996) investigated the effect of different enhancers on heparin 
across the human epidermis. The highest steady state flux values were achieved with the 
system containing Azone® as well as producing an enhancement ratio of 5.6. Azone® also 
produced an enhancement ratio of 11.4 for pentoxifylline from its gel formulation through full 
thickness rat skin (Yan et al., 2007). 
In addition to Azone® demonstrating activity on its own, the choice of a suitable solvent in 
the formulation may further increase the permeation of permeants across membranes. A 
solvent with good complimentary effects with Azone® would be propylene glycol. Chatterjee 
et al., (1997) indicated that Azone® and propylene glycol combination resulted in higher flux 
and lower lag values when compared to other enhancer and solvent combinations. It is 
suggested that reason for this increased permeation activity is that Azone® disrupts the lipid 
structure of the epidermis where the propylene glycol plays the role of solvating the keratin 
in the horny cell, displacing bound water and competing with the permeant/drug for 
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hydrogen bonding sites. The Azone® therefore, enhances intercellular drug transport and 
the propylene glycol may enhance intracellular transport (Goodman and Barry,1988).  
3.8.2  Sodium dodecyl sulphate (SDS) 
 
Sodium dodecyl sulphate (SDS) is an anionic, amphophilic surfactant with widespread 
topical application. Its activity has been related to a disruptive effect on the stratum corneum 
causing impairment of the skin barrier function as a result of the removal of intercellular 
hydrophobic lipids, which leads to an increase in transdermal water loss (Borra-Blasco et al., 
2004). 
SDS has the ability to insert itself between bilayers of lipids in the stratum corneum (Ribuad 
et al., 1994). This results in an increase in the flux value of the permeant. Borra-Blasco et 
al., (1997) reported when assessing the permeation of four different compounds with varying 
lipophicities that the effect of SDS decreases as the lipophilicity of the compounds 
increases. Similarly, Copovi (2006) indicated that SDS had no effect on compounds with a 
log P value of more than 3 and the most hydrophilic compound (log P -0.95) tested 5-
flourouracil, displayed the largest enhancement ratio. It follows the same permeability-
lipophilicity correlation as Azone® with various compounds with lipophilicity ranging from 
hydrophilic to hydrophobic (Borra-Blasco et al., 2004). 
3.8.3  Water 
 
When considering safety and effectiveness, water is the best permeation enhancer because 
most substances penetrate better through a hydrated stratum corneum than through dry 
tissue (Barry, 2001). This would be for hydrophilic and hydrophobic penetrants. The water 
content of the stratum corneum layer is between 15% and 20% of the dry weight, additional 
water in this layer could increase the solubility of the permeant leading to a modification of 
the partitioning from the vehicle to the stratum corneum (Benson, 2005). Benson (2005) also 
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suggested that hydration could cause swelling and opening of the stratum corneum resulting 
in increased permeation. Water used as a co-solvent to facilitate permeation may be due to 
its polar nature, interacting with the polar head groups of lipids in the stratum corneum and 
upsetting the packing nature of the polar arrangement (Suhonen et al., 1999). Williams and 
Barry (2004) suggested that “free” water within the tissue could cause an alteration of the 
solubility of a permeant in the stratum corneum resulting in modification in the partitioning 
from the permeant vehicle into the stratum corneum. They further suggested that a 
mechanism like this would explain the increase in drug flux of hydrophilic drugs due to 
increased hydration but does not explain how hydration causes an increase in permeation 
for lipophilic compounds.  
3.8.4  Ethanol 
 
Ethanol is the most commonly used alcohol for transdermal permeation enhancement 
(Heard et al., 2006; Sinha and Kaur, 2000). Concentrations of 30% may increase the lipid 
fluidity of the stratum corneum at polar interfaces (Suhonen et al., 1999), which could result 
in increased flux across membranes. Ethanol is an effective solvent for polar and non polar 
groups of structures and it is feasible that small quantities are capable of leaching significant 
quantities of non-covalently bound amphophilic stratum corneum lipids which would affect 
the skin barrier (Heard et al., 2006). It also increases the number of free sulphydryl groups of 
keratin in the proteins of the stratum corneum (Sinha and Kaur 2000). Higher concentrations 
of ethanol seem to promote permeation. Jantharaprapapa and Stagni (2007) reported the 
highest flux values with formulations consisting of ethanol at a concentration of 33%. 
Further, Thomas and Panchagula (2003) reported that the flux of AZT across the rat 
epidermis was highest in a formulation consisting of 66% ethanol compared to lower ethanol 
concentrations.  
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 When incorporating ethanol as an excipient or co-solvent, its volatility should be considered 
as it may vaporize from the formulation and affect the solubility of the remaining excipients in 
a formulation resulting in changed permeation potential over time (Morimoto et al., 2002). 
3.8.5  Propylene glycol 
 
The mechanism of action propylene glycol is suggested to be similar to that of ethanol, 
whereby the solvent partitions into the tissue facilitating the uptake of the drug into the skin 
with the possibility of small disturbances to intercellular packing of the lipids in the stratum 
corneum (Williams and Barry, 2004) 
Though, generally it seems that it has only moderate enhancement properties on its own 
(Williams and Barry, 2004). 
 When Propylene glycol is incorporated into a formulation, it is usually selected primarily for 
its solvent properties, which also happen to have permeation enhancement properties 
(Thomas and Panchagula 2003; Kim et al., 1993). It appears that the propylene glycol 
demonstrates enhanced activity, which aids other compounds to increase permeation across 
membranes (Williams and Barry, 2004; Wang et al., 2004). This was demonstrated by Yan 
et al., (2007) where various combinations of enhancers used with propylene glycol were 
investigated with the aim to increase the flux of pentoxifylline. Their study found that the 
combination containing propylene glycol obtained the highest flux value. However, in the 
absence of permeation enhancers in formulations, it has been reported that propylene glycol 
lacked the ability to increase permeation across membranes (Chatterjee et al., 1997; 
Goodman and Barry, 1988) 
However, higher concentrations of propylene glycol resulted in lower flux values. This was 
related to the dehydration of the epidermis leading to interlocking of polar head groups 
producing an increase in the barrier nature of the stratum corneum.  Similarly, Thomas and 
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Panchagula (2003) revealed that the presence of high concentrations (above 50%) resulted 
in a decreased hydration of the epidermis. 
3.8.6  Dimethsulphoxide (DMSO) 
 
Dimethsulphoxide (DMSO) is one of the most widely used and earliest studied permeation 
enhancers. It is colourless and hygroscopic and has been effective to promote enhancement 
of hydrophilic and hydrophobic permeants (Williams and Barry, 2004) Various mechanisms 
of activity have been suggested, which include denaturation of the intercellular structural 
proteins of the stratum corneum as well as increasing the lipid fluidity through disruption of 
the ordered structure of the lipid chains (Anigbogu et al., 1995). Even though it is commonly 
used there are concerns about its effects at high concentrations as it may result in 
denaturation of proteins and erythema in the stratum corneum. Side effects with the use of 
DMSO have been reported (Williams and Barry, 2004). 
3.8.7  1,8 Cineole 
 
Terpenes are found in essential oils and consist of hydrogen, carbon and oxygen atoms. 
The principal terpene element within eucalyptus oil is 1,8 cineole. 1.8 Cineole has the ability 
to promote the enhancement of hydrophilic and hydrophobic compounds (Rajan and 
Vasudevan, 2012). Anjos et al., (2007) reported that this compound may reach the center of 
a membrane bilayer where it increases the local mobility and volume of the fluid state of the 
membrane. 1,8 cineole has been used at concentrations ranging from 1% to 10% with 
permeation enhancement achieved with lipophilic and hydrophilic penetrants across human 
and animal membrane systems (Gao and Singh1997; Xiong et al., 1996; Ogiso et al., 1995). 
However, it is suggested that the activity of terpenes are dependent on the physiochemical 
properties of the penetrant and that the introduction of cineole may in certain cases, result in 
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a decrease in the permeation of the penetrant (Sinha and Kaur, 2000; Gao and Singh, 
1997). 
3.9   Synthetic membranes 
 
Synthetic membranes are used to elucidate information regarding mechanisms of 
permeation and enhancement properties of excipients from dosage forms and may serve as 
a precursor to testing before transdermal studies (Hauck et al., 2007; Al-Saidan, 2004; 
Clement et al., 2000; Schwarb et al., 1999). 
Human transdermal permeation experiments are a more realistic reflection of the permeation 
potential of a compound or delivery system but the availability of skin and the risk related 
with its use is a motivation to use preliminary studies with synthetic membranes (Clement P, 
et al., 2000). Synthetic membranes have demonstrated to share a common solubility-
diffusion mechanism of drug transport with the skin resulting in it being used for quantitative 
prediction of transdermal drug delivery and as a skin-imitating membrane in in vitro drug 
delivery evaluation (Dureja et al., 2001; Feldstein et al., 1998).  
The success of using of using synthetic membranes vary, Feldstein et al., (1998) reported 
that a synthetic carbosil membrane displayed similar responses to the permeability of a 
variety of compounds compared to human skin. Conversely, Al-Saidan  (2004) indicated no 
relation between a hydrophobic synthetic membrane and human skin with ibuprofen.  
Synthetic membrane models merely act as passive diffusional barriers and do not take into 
account the complexity of the human epidermis (Barbato et al., 1998).  
Synthetic membranes are generally classified as demonstrating hydrophilic or hydrophobic 
properties. The permeation profiles of permeants are dependent on the properties of 
synthetic membranes and formulations (Wang et al., 2006). 
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3.9.1  Sil-Tec® 
 
This silicone membrane with hydrophobic properties has been used with gel formulations 
containing propylene glycol: ethanol solutions for in vitro permeation testing (Salgado et al., 
2010; Schwarb et al., 1999). Sil-Tec® has also been used in the assessment of the in vitro 
permeation of the medicinal plant extracts S. Lutea from topical emulsions (Isaac et al., 
2012). 
3.9.2   Tuffryn® 
 
Tuffryn® is a polysulfone membrane with hydrophilic properties (Thakker and Chern, 2003). 
It has been used in in vitro diffusional studies for determining the reliability and 
reproducibility in the rate release profiles of topical dosage forms (Hauck et al., 2007). It has 
also been used in studies comparing the flux values of hydrophobic membranes and human 
skin (Megrab et al., 1995).  
Synthetic membranes may be used to elucidate information relating to drug release profiles 
from dosage forms, enhancement properties of excipients  and these membranes are used 
as precursors to transdermal permeation studies. 
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3.10  Other membrane systems 
 
Various other membrane systems have been explored to simulate the skin to observe the 
behavior of penetrants, permeation enhancers and other permeation promoting techniques. 
These membrane systems include natural membranes such as skin of fruit, snakeskin and 
other animal skin models (Ansari et al., 2006; Thomas and Panchagula 2003; Haigh et al., 
1998). Laboratory design membranes include liposomal suspensions containing lipids and 
chitosan layered membranes (Dureja et al., 2001; Abraham and Downing, 1989). The 
disadvantage of non-skin membrane systems is that they do not contain active components 
which the skin possess and therefore, it is difficult to replicate permeation across the skin 
even though permeation is a passive process. Therefore, animal skin models are probably 
the closest models that may be used as a substitute for human skin with porcine skin, 
guinea pig and rat skin model commonly used (Abdelouahab and Heard, 2008; Morris et al., 
2009; Karende et al., 2007; Anjos et al., 2007; Wang et al., 2004). 
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CHAPTER FOUR:  Identification and Quantification of  
    compounds in Harpagophytum   
    procumbens extract. 
 
Harpagoside and harpagide glycosides are present in the crude Harpagophytum 
procumbens extract and were used as marker compounds in the extract. These markers 
were identified and quantified using thin layer chromatography (TLC), UV spectroscopy, high 
pressure liquid chromatography (HPLC) and densitometry.  
4.1  Methods 
4.1.1  Extraction of Harpagophytum procumbens. 
 
Although the dried Harpagophytum procumbens (A. White Chemist, South Africa) was not 
authenticated by a taxonomist at the University of the Western Cape, identification of the 
marker compounds in the plant extract was verified against certified standards with 
certificates of analysis. The plant root was cut into small manageable pieces and powdered 
using a hammer mill (Cullati, Germany) with decreasing aperture sizes. The resultant 
powder was collected and weighed. 250g of the powder was placed into 2.5 L containers 
and methanol (Merck, South Africa) added for extraction. The containers were not filled 
beyond two thirds of its volume in order to promote agitation and subsequent extraction. This 
mixture was agitated with a shaker (Labcon, USA) for 6 hours followed by centrifugation 
(Beckman J2-21, USA) for 30 minutes at 10000 rpm. After centrifuging the supernatant was 
carefully removed, filtered with filter paper (Whatman, No.1) and collected. The filtered 
supernatant was transferred in aliquots of 200ml into round bottom flasks, sealed, foiled 
wrapped and stored at -20° C. 
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4.1.2  Rotary Evaporation 
 
Solvent removal was performed using a Rotavapour (Buchi R II, Germany) under reduced 
pressure while heated to a temperature not exceeding 40°C (European Pharmacopoeia, 
2004). This process of methanol reduction was maintained until a resinous extract was 
formed with no further solvent loss and constant mass maintained. The resinous crude 
extract was, sealed, foiled wrapped and stored at -20° C. 
4.1.3  Thin layer chromatography 
4.1.3.1 Comprehensive Two-dimensional chromatography 
 
Thin layer chromatography (TLC) including two dimensional thin layer chromatography was 
used for the identification and purification of the marker compounds harpagoside and 
harpagide in the Harpagophytum procumbens extract using TLC plates (silica gel 60, F254, 
Merck, South Africa).  The chromatograms were examined under UV-light at 254 nm for the 
detection of individual compounds. The mobile phases used were solvent systems 
containing butanol, acetic acid and water (12:3:5) (BAW) and ethyl acetate, methanol, water 
(77:15:8) (EMW). All solvents were obtained from (Merck, South Africa). Samples were 
spotted for first dimension chromatography, dried, rotated 90° and again chromatographed 
in the second dimension with the second solvent system. 
4.1.3.2        Identification of marker compounds.  
4.1.3.2.1 Harpagide and Harpagoside standard preparation.  
 
Stock solutions of harpagoside and harpagide standards (PhytoPlan®, Germany) were 
prepared with methanol. The stock solutions were stored at less than4°C. All experimental 
TLC plates included the presence of standards. 
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4.1.3.2.2 TLC Spraying colouring reagent. 
 
The TLC spraying reagent contained 1% (w/v) vanillin (Sigma-Aldrich, South Africa), 1% 
methanol, 5% sulfuric acid,  (Merck, South Africa). The spraying reagent was prepared by 
adding sulphuric acid to methanol followed by the addition of vanillin and made up to the 
appropriate volume with ethanol. This was gently agitated until a clear solution was formed. 
The reagent was applied to TLC plates by means of an aerosol-spraying device.  
4.1.3.2.3 Harpagide identification. 
 
Thin layer chromatography analysis was performed with crude extract at a concentration of 
400 mg/ml. Two-dimensional TLC chromatography was implemented as illustrated in figure 
4.1 based on the method as described by Ciesla  and Waksmundzka-Hajnos, (2009).  Five 
microlitres of the crude extract  (A) as well as the pure harpagide standard (B) were spotted 
on the TLC plates and then chromatographed over a plate length of 8 centimeters (1st 
dimension) with BAW (12:3:5) as eluent. The TLC plates were air dried and observed under 
UV light at a wavelength of 254 nm. The visible chromatographed spots under the UV light 
were marked with a pencil. The TLC plate was rotated 90° anticlockwise.  At this position, 
5µl harpagide standard (C) was spotted and chromatographed in the second dimension with 
a solvent system consisting of EMW (77:15:8) as illustrated in figure 4.1. The TLC plate was 
air dried, viewed under UV light and sprayed with the TLC colouring reagent. It was then 
heated for 5 minutes at 80ºC in an oven yielding identifiable visible spots (Wichtl, 2004). 
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   Figure 4.1 Two-dimensional TLC of Harpagophytum 
 procumbens crude extract for harpagide identification  
 with 2 solvent systems. 
 
  
4.1.3.2.4 Harpagoside identification. 
 
Thin layer chromatography was performed with crude extract at a concentration of 400 
mg/ml.  Five microlitres of the extract (A) as well as the harpagoside standard (B) was 
applied to the TLC plate and chromatographed over a plate length of 8 centimeters with the 
BAW solvent system (figure 4.2). The TLC plate was air-dried, observed under UV light at a 
wavelength of 254 nm. The visible spots under the UV light were marked with a pencil.  The 
90°	
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TLC plate was sprayed with the colouring reagent. The TLC plates were heated for 5 
minutes at 80ºC in an oven yielding identifiable visible spots (Wichtl, 2004). 
 
 
Figure 4.2 TLC plate of Harpagophytum 
procumbens crude extract for harpagoside 
 identification. 
 
 
4.1.4  Densitometry 
 
After the TLC plates were sprayed with the colouring reagent to identify the compounds, it 
was scanned using a scanner connected to a laptop computer with specialized Quantiscan® 
software version 3 (Biosoft®, England) for the purpose of further identification and 
quantification as described by Nikolova and Velickovic (2004). The scanned TLC images 
were digitally converted with the software and each spot was individually quantified. The 
quantification results were represented in units that correspond to colour intensity. 
 
Crude extract 
 
A B 
Harpagoside std 
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4.1.5  Purification of marker compounds from crude extract. 
 
 The crude drug (400 mg/ml) was carefully streaked across the glass TLC plate with a glass 
pipette (figure 4.3). The tip of a glass pipette was modified for slow movement of the crude 
sample from the pipette to ensure a narrow streaked area A of crude extract. The prepared 
standards of harpagide or harpagoside were spotted on the TLC plate (segment B in figure 
4.3). The TLC plate was placed in a (BAW) solvent saturated TLC chamber, 
chromatographed and air-dried. The plates were then covered with a glass sheet except for 
segment B. This exposed area was sprayed with the TLC colour reagent spray and dried as 
previously described.  
 
 
   Figure 4.3 Purification of marker compounds 
from crude resinous extract with a streaking  
technique. 
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B 
A 
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After chromatography, the resultant harpagoside or harpagide bands from the crude extract 
on the TLC plates were marked according to the corresponding Rf values of the standards in 
segment B of the plate. The marked area was removed by scrapping the silica from the TLC 
plate with a narrow spatula and suspended in 1 ml methanol. After agitation (Infors HT, 
Switzerland) for 10 minutes, it was then vortexed for 5 minutes. Thereafter, it was 
centrifuged at 5000 rpm for 20 minutes (Hëttich®, Germany) and the supernatant (methanol 
phase) was carefully removed from the pellet. This process was repeated for the purpose of 
sample enrichment. 
4.1.6  Removal of solvent from supernatant. 
 
After centrifugation, the supernatant was concentrated by the removal of the methanol. This 
was done by transferring it to 8 ml Greiner® vials and placed in a digital dry bath (Labcon®, 
United Kingdom) set at a temperature of 37º C under a gentle stream of nitrogen via a 
manifold. This evapouration process took about 2 hours resulting in a resinous extracts of 
harpagoside and harpagide. These purified extracts were stored at -20º C. 
4.1.7  UV-spectroscopy for Harpagoside identification. 
 
Confirmative UV-spectroscopy on the purified harpagoside was performed. The UV 
spectrum of the TLC purified harpagoside was determined by UV-spectroscopy (Cintra® 
202, Australia) in phosphate buffered saline (PBS) at pH 7. A wavelength scan range was 
set between 190– 500 nm, which was within the λmax for harpagoside. The TLC purified 
sample was dissolved in PBS then filtered with a 0.45 μm filter. Absorbance was measured 
against phosphate buffered saline (PBS) blank. The sample was diluted by serial dilutions in 
order to obtain an absorbance range of between 0-1 for increased accuracy. 
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4.1.8  High Pressure Liquid Chromatography 
 
High pressure liquid chromatography system consisted of a Hewlett Packard® Agilent® 
1200 series system. A Phenomenex® (Luna C-18, 20 x 4.5 mm, 5 μm) with a pre-guard 
filter. Agilent® Chemstation® software package was used for analysis of data. 
 Two HPLC methods were used. The first system consisted of a flow rate of 1.5 ml/ minute 
at a wavelength of 210 nm with a gradient mobile phase   Methanol: Water (30%- 60% 
gradient) over 10 minutes. Chlorocresol was used as an internal standard. 
  The second method consisted of an isocratic mobile phase system. For harpagide 
detection, a flow rate of 1.5 ml/minute at a wavelength of 210 nm with a 20% methanol/ 
buffer (50 mM K2HPO4 -KH2PO4) mobile phase was used. For the harpagoside detection, a 
flow rate of 1.5ml/minute was used at a wavelength of 278 nm with a 60% methanol/ buffer 
(50 mM K2HPO4 -KH2PO4 buffer) mobile phase. 
 
  
 
 
 
 
57 
 
4.2.   Results and Discussion 
4.2.1   Thin layer chromatography identification of  Harpagide and  
   Harpagoside. 
4.2.1.1 Harpagide identification 
 
For harpagide identification, two-dimensional TLC was used. The first dimension of the TLC 
plates developed over a distance of 8 centimeters (figure 4.4). When observed under UV 
light at a wavelength of 254 nm, 3 identifiable bands were visible (black circles). These were 
bands 1, 2 and 3 with their respective Rf values listed in table 4.1. As expected, the spotted 
harpagide standard was not visible under UV light. After the TLC plate was sprayed with the 
colouring reagent spray, 3 additional spots appeared, numbered 4, 5 and 6.  
 
   Figure 4.4 Thin layer chromatography of  
Harpagophytum procumbens extract. Butanol, 
acetic acid and water (BAW) (12:3:5) solvent system. 
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This included the harpagide standard (spot 6) revealing an Rf value of 0.37. This value 
corresponded to the Rf value of band 5 of the spotted crude Harpagophytum procumbens 
extract. In addition, these two spots where not visible under UV light. When sprayed with the 
colouring agent, they appeared the same violet-red colour.  The colour was the same as 
described by Wichtl (2004) in identifying harpagide with the same spraying solution. Spot 
number 5 had the same colour as spot 6 but more faint, this may be as a result of its lower 
concentration compared to the harpagide standard (spot number 6.) 
Table 4.1. Rf values of compounds in Harpagophytum procumbens extract with 
butanol, acetic acid and water (BAW) solvent system (1st dimension). 
 
TLC spot number 
 
Rf Value 
 
Spot Colour after spraying 
1 0.93 Colourless 
2 0.82 Colourless 
3 0.68 dark red 
4 0.42 grey/purple 
5 0.37 dark red 
6 0.37 dark red 
 
To confirm spot 5 as the harpagide present in the crude extract, a two-dimensional TLC 
solvent system was implemented.   
Figure 4.5 presents the TLC plate chromatographed and developed over the second 
dimension. The second system consisted of EMW followed by spraying with the colouring 
reagent spray. In the second dimension, the solvent front was 8 cm. Spot number 5 from the 
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first dimension (indicated by X) migrated to form spot number 9. The yellow arrow indicates 
the migration pattern of spot 5 over the two dimensions. 
 
  Figure 4.5 Thin layer chromatography of Harpagophytum  
procumbens extract. Ethyl acetate, methanol and water 
 (EMW) (77:15:8) solvent system. 
                                    
 
 
Spot 7 was the harpagide standard from the first dimension. The second harpagide standard 
spotted in the second dimension migrated to form a dark red spot (spot 8) with Rf value of 
0.19 (table 4.2). This corresponded in colour and Rf value to band number 9. Spot 9 
corresponded horizontally and vertically to the harpagide standards in the first and second 
dimension (spot 7 and 8) respectively with respect to  Rf values. 
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Table 4.2. Rf values of compounds in Harpagophytum procumbens extract with ethyl 
acetate, methanol and water solvent system (EMW) (2nd dimension). 
 
TLC spot number 
 
Rf Value 
 
Spot Colour after spraying 
7 0.37 dark red  
8 0.19 dark red 
9 0.19 dark red 
 
This in addition to the colour of spot 9 being the same as the harpagide standards and that 
none of these spots were visible under UV light 254 nm, confirms that spot 9 is the 
harpagide component present in the Harpagophytum procumbens extract. 
4.2.1.2 Harpagoside identification 
 
TLC plates were chromatographed using the mobile phase consisting of BAW and 
developed over a distance of 8 centimeters (figure 4.6). When observed under UV light at a 
wavelength of 254 nm, four identifiable spots were observed. These were bands labeled 1, 
2, 3 and 6, with their respective Rf listed in table 4.3. Spot 3 with an Rf value of 0.68 
corresponded to the Rf value of the pure harpagoside standard (spot 6). Two-dimensional 
chromatography was not performed with harpagoside. 
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Figure 4.6 Thin layer chromatography of 
Harpagophytum procumbens extract. Butanol, acetic 
    acid and water (BAW) (12:3:5)  solvent system. 
\  
 
 
Table 4.3. Rf values of compounds in Harpagophytum procumbens extract with 
butanol, acetic acid and water solvent system (BAW). 
TLC spot number Rf Value Spot Colour after spraying 
1 0.93 colourless 
2 0.82 colourless 
3 0.68 dark red 
4 0.42 grey/purple 
5 0.34 dark red 
6 0.68 dark red 
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After the TLC plate was sprayed with the colouring reagent spray, 2 additional spots 
appeared, numbered 4 and 5 with Rf values of 0.42 and 0.34 respectively. 
 Spots number 3 and 6 which had the same Rf value, were visible under UV light was also 
coloured, appearing as violet red bands. The colour, which developed, is the same as 
described by Wichtl (2004) in identifying harpagoside with the same spraying solution. Spot 
5 had the same colour but was less intense probably as a result, its lower concentration.  
Spot 4 appeared as a faint grey/purple spot (does not appear clearly on the photograph). 
To confirm spot five as harpagoside, it was collected and purified from preparative plates 
and analyzed spectrophotometrically to observe its UV spectrum. The UV spectra of the 
purified compound (figure 4.7) were identical to that of the harpagoside standard (figure 4.8) 
with a ratio of peak maxima (280 nm) to minima (233 nm) of 1.87. 
Figure 4.7. UV spectrum of TLC purified harpagoside in Harpagophytum procumbens 
extract dissolved in PBS. 
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Figure 4.8. UV spectrum of pure harpagoside standard dissolved in PBS. 
 
 
4.2.2  Quantification of harpagoside and harpagide by    
  densitometry. 
 
The TLC plates containing the harpagide and harpagoside from Harpagophytum 
procumbens extract were quantitatively densitometrically analyzed for their harpagoside and 
harpagide contents using the Biosoft® Quantiscan software.  After spraying the TLC plate, it 
was scanned and digitally manipulated with the software (figure 4.9).  
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Figure 4.9. Sprayed TLC plate digitally    
 converted with Biosoft® Quantiscan    
 software. 
 
 
The densitometry software allows the spots on the TLC plates to be analyzed on X – 
position and Y- positions. From figure 4.10 it can be observed that harpagoside in the crude 
extract appears on the same Y- position (80) as that of the harpagoside standard (79).  
Similarly, the developed spots of harpagide in the crude extract and the harpagide standard 
also appear along the same Y- position with values of 145 and 143 units respectively. 
 
 
  
Harpagoside  
Harpagide 
Harpagide 
Harpagoside  
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Figure 4.10.  Digital densitometry of TLC spots of 
 harpagoside and harpagide. 
 
      
The densitometric analysis revealed a total volume count for harpagoside and harpagide 
from Harpagophytum procumbens extract of 16363 units and 6147 units respectively. In 
addition, a known quantity (0.07 mg) of harpagoside and harpagide standards where spotted 
on the same TLC plate resulting in net volumes of 18239 units and 21316 units respectively. 
The quantities were extrapolated with a standard curve using the values of TLC spotted 
harpagoside and harpagide standards (table 4.4). The harpagoside and harpagide in the 
extract represented quantities of 0.06mg and 0.02 mg respectively. The sample standards 
spotted on the same plate produced a quantity of 0.07 mg for harpagoside and 0.07 mg for 
harpagide from the standard curve. 
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Table 4.4. Harpagoside and harpagide standards spotted on TLC    
plates with corresponding densitometric volumes.  
Quantity of pure 
standard (mg) 
Harpagoside 
volume (units) 
Harpagide 
volume (units) 
0.08 21411 24418 
0.06 16670 18831 
0.04 10888 12552 
0.02 5222 6214 
 
Figure 4.11 is a 3 dimensional graphical quantitative and positional representation generated 
by the Biosoft® software of the developed spots on the TLC plate where the volume of the 
peaks is proportional to its concentration. It can also be seen that the two harpagide peaks 
(1 and 2) appear on the same axis and the two harpagoside peaks appear on the same axis 
(3 and 4). 
Figure 4.11. Three dimensional quantitative and positional representation   
TLC harpagide and harpagoside spots. 
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The quantitative analyses of the compounds screened on the developed TLC plates 
indicated that the tested Harpagophytum procumbens extract contained 3% harpagoside 
and 1% harpagide. This result is similar to that of Bruneton (1999) who reported the quantity 
of iridiode glycosides, which include harpagoside and harpagide, present in the 
Harpagophytum procumbens crude extract to be between 0.5% and 3%. Wichtl (2004) 
reported the quantity of harpagoside present in the crude extract to be 1.5% and varies with 
the quality of the crude drug. 
The quantity of components yielded may also vary depending on the extract technique 
implemented. Different extraction techniques may result in diverse fractions of the crude 
being yielded (Loew et al., 2001). These extraction techniques may vary in the solvent 
systems being used, temperature as well as crude drug particle size (Gunther et al., 2006). 
 Gunther et al., (2006) demonstrated through experimental manipulation of the mentioned 
variables that harpagoside yields of between 20 and 30% were obtainable from the crude 
Harpagophytum procumbens extract. However, the study also revealed that when 
conventional extraction procedures were implemented, the harpagoside content in the crude 
extract was as low as 2.5%. The conventional techniques involve particle size reduction, and 
agitation with a solvent similar to the technique used in our study. 
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4.2.3  High pressure liquid chromatography (HPLC) 
 
The chromatogram consisting of harpagide, harpagoside and chlorocresol standards are 
presented in figure 4.12.  
   Figure 4.12 Chromatogram of Harpagophytum procumbens extract. Mobile phase: 
  30-60% methanol gradient at wavelength 210 nm.  
 
 
The chromatograms of the crude Harpagophytum procumbens extract (figure 4.12) and the 
standards (figure 4.13) were superimposed in order to identify the harpagoside and 
harpagide in the crude extract (figure 4.14). The retention times of the standards, which 
corresponded to the peaks on the chromatogram of the crude extract, were identified. This 
chromatogram indicates retention times of 2.2 minutes for harpagide, 8.7 minutes for 
harpagoside and 9.3 minutes for the chlorocresol used as internal standards. This method 
was also utilized for partition co-efficient experiments with the harpagoside and harpagide 
marker compounds with the various permeation enhancers and gel formulations. 
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Figure 4.13 Chromatogram of pure harpagoside and harpagide drug standards. 
 Mobile phase: 30-60% methanol gradient at wavelength 210 nm. 
 
 
Figure 4.14 Superimposed chromatogram of Harpagophytum procumbens 
 extract, pure harpagoside and harpagide standards. Mobile phase: 30-60% 
 methanol gradient at wavelength  210 nm. 
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Due to sensitivity and interfering substances, the HPLC method used was modified. An 
isocratic HPLC method was used at two different wavelengths. For the harpagide, a 20% 
methanol/buffer (50 mM K2HPO4 + KH2PO4) was used at a wavelength at 210 nm. For 
harpagoside, a 60% methanol/buffer (50 mM K2HPO4 + KH2PO4) mobile phase was used at 
a wavelength of 278 nm. These wavelengths represent the maximum UV absorbance for 
harpagide and harpagoside respectively. 
In these systems, harpagide standard had a retention time of 2.1 minutes (figure 4.15) and 
4.5 minutes for harpagoside (figure 4.16). 
 
  Figure 4.15 Chromatogram of pure harpagide standard. Mobile phase: 20% 
 methanol/buffer (50mM K2HPO4 + KH2PO4) at wavelength 210 nm. 
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Figure 4.16 Chromatogram of pure harpagoside standard. Mobile phase: 60% 
methanol/buffer (50 mM K2HPO4 + KH2PO4) at wavelength 278 nm. 
 
 
With the isocratic mobile phase method, the harpagide peak was identified in the crude 
sample by superimposing the chromatogram of Harpagophytum procumbens with this 
sample containing spiked quantities of harpagide standard (figure 4.17), This method of 
identification was used for the identification for harpagoside as well (figure 4.18).  
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Figure 4.17 Superimposed chromatograms of  Harpagophytum procumbens extract 
alone, and spiked with pure harpagide standard. Mobile phase: 20% methanol/buffer 
(50 mM K2HPO4 + KH2PO4) at wavelength 210 nm. 
 
 
Figure 4.18 Superimposed chromatograms of Harpagophytum procumbens extract 
alone, and spiked with pure harpagoside standard. Mobile phase 60% methanol/buffer 
(50 mM K2HPO4 + KH2PO4) at wavelength 278 nm. 
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Confirmative identification of harpagide and harpagoside was performed by comparing the 
UV spectra of the identified harpagide and harpagoside peaks in the crude Harpagophytum 
procumbens sample with that of pure standards, with the harpagide not displaying a UV 
spectra (figure 4.19) and harpagoside with a peak maxima to minima at wavelength of 280 
nm and 233 nm, with a ratio of 1,187 (figure 4.20). The UV spectra of the identified 
harpagide and harpagoside peaks in the crude sample corresponded to the respective 
spectra of the harpagide and harpagoside standards. 
 
Figure 4.19. UV spectrum of the harpagide peak     
from crude Harpagophytum procumbens extract. 
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Figure 4.20 UV spectrum of the harpagoside peak   
  from crude Harpagophytum procumbens extract.  
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4.3  Conclusion 
 
Harpagide and harpagoside marker compounds were identified in the crude Harpagophytum 
procumbens extract. Two-dimensional thin layer chromatography of the identified harpagide 
in the crude extract yielded an identical Rf = 0.19 value and dark red colour when compared 
to the harpagide standard. One-dimensional chromatography of the harpagoside compound 
yielded an Rf value of 0.68 with a dark red colour, which was identical to the harpagoside 
standard. As with the harpagide standard, the harpagide identified in the crude extract also 
did not display a UV spectrum. The UV spectra of the identified harpagoside on the TLC 
plate in the crude extract and harpagoside standard were identical with a peak maxima to 
minima ratio of 1.87. The HPLC analysis of the crude extract identified harpagide and 
harpagoside by having identical retention times and UV spectra to the respective standards. 
Harpagide and harpagoside were densitometrically quantified in the crude Harpagophytum 
procumbens extract to be 1% and 3% respectively. 
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CHAPTER FIVE: Pre- Transdermal Cyclooxygenase-2  
    enzyme inhibition 
 
 
Content of this section has been reproduced from the Article titled “Direct inhibition of 
Cyclooxygenase-2 enzyme by an extract of Harpagophytum procumbens, harpagoside and 
harpagide” by N Ebrahim and R Uebel, African Journal of Pharmacy and Pharmacology Vol. 
5(20),  2209-2212, 29 November, 2011 (See annexure I for full-length article). 
 
The Harpagophytum procumbens extract and the two marker compounds (harpagide and 
harpagoside) were tested for their pharmacological ability to directly inhibit the 
Cyclooxygenase-2 enzyme, which would be an indication of their anti-inflammatory 
properties. Further, the COX-2 inhibition experiments were also used to determine whether 
the crude extract retained its COX-2 inhibition activity after permeation across human skin 
membrane. 
5.1  Methods 
5.1.1  Pre-Permeation COX-2 enzyme inhibition activity. 
 
COX-2 activity was determined spectrophotometrically (Cintra® 202, Australia) by 
measuring UV absorption change of the reaction mixture at a wavelength of 610 nm exactly 
8 minutes after initiating the reaction against the appropriate blank. COX-2 inhibition 
experiments were based on the methods reported by Copeland et al., (1994) and Corazzi et 
al., (2005) with minor changes.  
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5.1.1.1 Purified COX-2 enzyme 
 
Purified COX-2 (ovine) enzyme (Cayman Chemical, USA) was stored at -80°C and 
maintained on dry ice during experiments. Twenty-five units (4µl) of the enzyme was added 
to the enzyme reaction buffer solution. 
5.1.1.2 Enzyme reaction Buffer  
 
The buffer consisted of 100 mM sodium phosphate pH 6.5, 0.5 µM hematin (Sigma-Aldrich, 
South Africa), and 1mg/ml gelatin (Sigma-Aldrich, South Africa).  
5.1.1.3 Enzymatic reaction 
 
The enzymatic reaction was initiated by adding 100 µM of arachadonic acid (Sigma-Aldrich, 
South Africa) and 50 µM N,N,N’,N’– tetramethyl-p-phenylenediamine (TMPD) (Sigma-
Aldrich, South Africa) to a final reaction mixture of 1000 µl buffer solution in laboratory 
temperatures not exceeding 20º C. Arachadonic acid and TMPD were freshly prepared 
when experiments were performed. For COX-2 inhibitory activity determination, 
Harpagophytum procumbens extract, harpagoside and harpagide were dissolved in 
dimethsulphoxide (DMSO) (Merck, South Africa) and added to the reaction solution buffer 15 
minutes before arachadonic acid and TMPD were added.  DuP-697 was dissolved in 
dimethylformamide (Merck, South Africa) instead of DMSO due to its relatively poor solubility 
in DMSO.  The enzyme activity was measured by determining the rate of TMPD oxidation as 
indicated by the increase in the absorbance at 610 nm. 
5.1.1.4 Spectroscopy 
 
Fixed wavelength, confirmative UV-spectroscopy (Cintra 202, Australia) was performed with 
the Harpagophytum procumbens extract harpagoside and harpagide at different 
 
 
 
 
78 
 
concentrations in phosphate buffered saline (PBS). Fixed wavelength (610 nm) UV 
spectroscopy was performed with various reaction mixtures. Absorbance was measured 
against phosphate buffered saline (PBS) blank. The fixed wavelength absorbance reading 
was recorded at 30 second intervals for 10 minutes. No change of initial absorption values 
indicated 100% inhibition and maximum absorption change in the reaction without added 
inhibitors indicated zero inhibition. Data was fitted into GraphPad® Prism version 5 software. 
The following reaction mixtures were prepared: 
 Standard COX-2 reaction mixture - Arachadonic acid (AA) 100 µM + N,N,N’,N’– 
tetramethyl-p-phenylenediamine (TMPD) 50 µM  +COX-2 enzyme 4 µl (25 units)   + 
buffer solution up to 1000 µl. 
  Sample reaction mixture -Arachadonic acid (AA) 100 µM + N,N,N’,N’– tetramethyl-
p-phenylenediamine (TMPD) 50 µM  + COX-2 enzyme 4 µl (25 units)   + 
Harpagophytum  procumbens crude extract or harpagoside or harpagide 50 µl 
+ buffer solution up to 1000 µl. 
 Reference inhibition reaction mixture - Arachadonic acid (AA) 100 µM + N,N-
,N’,N’– tetramethyl-p-phenylenediamine (TMPD) 50 µM  + COX-2 enzyme 4 µl (25 
units)   + DuP-697 50 µl + buffer solution up to 1000 µl. 
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5.2  Results and Discussion 
 
5.2.1   COX-2 enzyme inhibition 
 
Figures 5.1 to 5.4 represent the illustrative absorbance versus time graphs for the COX-2 
inhibitory activity of various compounds including the crude Harpagophytum procumbens 
extract, harpagoside, harpagide and reference compound, DuP-697. The absorbance is 
associated with the oxidation of TMPD due to the activity of the COX-2 enzyme. Therefore, 
increased absorbance readings are associated with higher enzymatic activity and lower 
absorbance reading would indicate decreased COX-2 enzymatic activity (greater inhibition). 
The graphs were extrapolated and fitted to time zero using GraphPad® Prism 5 software. 
The standard reaction contains all the components of the reaction mixture excluding 
inhibitors. COX-2 absorbance at time 8 minutes was used in the measurement of inhibitory 
activity as this was determined to be the point of maximum absorbance from the data. The 
absorbance versus time graph indicates that inhibitory activity for most of the reactions were 
similar for the first 3 minutes of the reaction, the exceptions being the potent DuP-697 
inhibitor and Harpagophytum procumbens extract at 2mg concentration.   
 
Figure 5.1 UV absorbance vs. time of Harpagophytum procumbens 
    extract at various dilutions. 
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Figure 5.2 UV absorbance vs. time of Harpagophytum procumbens 
 and harpagide at various dilutions. 
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Figure 5.3  UV absorbance vs. time of Harpagophytum procumbens 
 and harpagoside at various dilutions. 
5 1 0 1 5
-0 .0 1
0 .0 0
0 .0 1
0 .0 2
0 .0 3
0 .0 4
H  P ro c u m b e n s  e x tra c t 0 .0 2 m g
H a rp a g o s id e  0 ,2  m g
H a rp a g o s id e  0 ,0 0 6  m g
S ta n d a rd  C O X 2  re a c t io n
M in u te s
A
b
s
o
r
b
a
n
c
e
 
 
     Figure 5.4 UV absorbance vs. time of DuP-697 at various dilutions. 
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The COX-2 inhibitory activity of Harpagophytum procumbens and DuP-697 were tested at 
various dilutions with the highest concentration being 2.0 mg and 0.12 mg respectively. At 
these maximum concentrations, 80% inhibition was achieved for the Harpagophytum 
procumbens and 96% for DuP-697 as can be seen from table 5.1. At the maximum dilution 
tested, 1:10 000 the Harpagophytum procumbens did not display any inhibitory activity while 
the DuP-697 displayed 18% inhibitory effect. 
Table 5.1 COX-2 % inhibition of Harpagophytum procumbens and DuP-697 at varying 
dilutions.(Highest concentration-Harpagophytum procumbens 2.0mg and DuP-697 0.12mg ) (Mean±SD, n=3) 
 Highest 
concentration 
(1:10) (1:100) (1:1000) (1:10 000) 
Harpagophytum 
procumbens 
80% (2.1) 68%(2.1) 24% (1.0) 2 % (0.3) 0%(0) 
Dup -697 98% (0.6) 85% (0.5) 66% (0.5) 58.5 (0.6) 18% (0.5) 
 
Figure 5.5 compares the COX-2 inhibition of Harpagophytum procumbens and DuP-697 
extract at 10 fold dilutions, starting at 2mg (80% inhibition) and 0.12 mg (98% inhibition)  
respectively. The DuP-697 starting concentrations was 17 times lower than that of the 
extract but exerted a greater inhibitory effect at lower concentrations (1:1000 dilution) than 
Harpagophytum procumbens extract. The difference in the inhibition decreases to less than 
20% at higher extract concentrations (1:10 dilution).  
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Figure 5.5 COX-2 inhibition curves     
 (pre-permeation)of DuP-697 and Harpagophytum   
  procumbens extract at various dilutions. 
 
 
When comparing the Harpagophytum procumbens extract to the DuP-697 inhibitor, the 
resultant inhibition curve indicated a non-linear COX-2 inhibition at low and high 
concentrations. This could suggest the presence of possible synergistic or polyvalent activity 
of compounds in the extract. 
Figure 5.6 Direct COX-2 enzyme inhibition (pre-permeation) by Harpagophytum 
procumbens extract, harpagoside and harpagide. (n=3; mean ±S.D.) 
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Figure 5.6 illustrates direct COX-2 inhibition by Harpagophytum procumbens extract as well 
as harpagoside and harpagide. At a concentration of 0.2 mg, Harpagophytum procumbens 
extract demonstrated direct enzyme inhibition of 68.3% (the highest concentration at the 
linear part of the crude extract’s inhibition), harpagoside 5% and harpagide 60%. When 
enzyme inhibition of harpagoside and harpagide were tested at 0.006 mg and 0.002mg 
respectively, this is the quantity that these compounds are represented in 0.2 mg of the 
crude Harpagophytum procumbens extract, only 1% and 9% direct inhibition were obtained 
respectively. The One Way ANOVA test indicated the data was statistically significant. The 
Tukey’s multiple comparison indicated that the difference in the % COX-2 inhibition for all 
samples tested in Figure 4.6 was statistically significant (P ≤ 0.05) when compared to the 
reference compound DuP-697 (1:10 dilution. 0.012mg). 
5.2.2  IC50 values  
 
The calculated IC50 values derived from inhibition studies are listed in table 5.2. The 
reference compound DuP-697 resulted in the lowest IC50 value (0.000134 mg/ml). 
Harpagide achieved higher COX-2 inhibition activity (IC50 of 0.1186 mg/ml) than harpagoside 
as direct inhibitor but less than Harpagophytum procumbens extract and DuP-697. 
Table 5.2. IC50 values of DuP-697, Harpagophytum procumbens 
 extract, harpagide and harpagoside as COX-2 inhibitors. 
 
 
 
 
 
  
Compound  IC50 mg/ml 
DuP-697  0.000134 
Harpagophytum procumbens extract 0.1046 
Harpagide 0.1186 
Harpagoside 104.1 
 
 
 
 
84 
 
The COX-2 inhibition experiments demonstrate direct inhibition (direct inhibition of the 
enzyme activity by the inhibitor) of the cyclooxygenase-2 enzyme with a crude extract of 
Harpagophytum procumbens, harpagide and to a lesser extent harpagoside.  
Previous studies report mainly on the inhibitory activity of Harpagophytum procumbens and 
its active compounds through indirect mechanisms of activity. This includes mechanisms of 
reduced enzyme expression or measuring enzymatic output through various biochemical 
pathways and not direct inhibition as in this study.  Examples of indirect inhibition are studies 
measuring COX-2 inhibition through TPA-induced COX-2 expression where the crude 
Harpagophytum procumbens extract inhibited the in vivo activation of transcription factors 
such as activator protein-1 and cyclic AMP (Kundu et al., 2005) in mice skin. Another 
example of measuring indirect COX-2 inhibition is shown in the study Jang et al., (2003) that 
measured inhibition by observing lipopolysaccharide-stimulated cyclooxygenase expression 
by measuring prostaglandin synthesis in mouse fibroblast cells. 
 When comparing the results of this study with other in vitro or in vivo studies which focus on 
indirect inhibition were, however, able to compare the extent to which inhibition of the COX-2 
by Harpagophytum procumbens and its active components has occurred even though the 
mechanisms of achieving this inhibition is different. 
 The extent of inhibition activity of the crude extract in this study is similar to the results 
obtained by Jang et al., (2003) and Kundu et al., (2005). Jang et al., (2003) reported COX-2 
inhibition of up to 70% percent through inhibition of expression of prostaglandin-2 in the 
presence of Harpagophytum procumbens. The Kundu et al., (2005) study revealed a 46% 
percent COX-2 inhibitory effect by the crude extract Harpagophytum procumbens when 
compared to their standard reaction not containing the crude extract. Benito et al., (2000) 
also reported that harpagoside was able to produce 30% inhibition of the release of the 
prostaglandin-2 which is a product of the cyclooxygenase enzymes, the same study 
indicated that harpagide was unable to produce prostaglandin-2 inhibition. 
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Abdelouahab and Heard (2008) reported that Harpagophytum procumbens and harpagoside 
produced COX-2 expression of about 50%  in the porcine ear epidermis. Further, their study 
also indicated that instead of producing inhibitory COX-2 inhibitory effects as found in our 
study, harpagide increased COX-2 expression, which the authors suggested contributed to 
an inflammatory response.  
The Abdelouahab and Heard (2008) study indicated that with the exception of harpagide that 
the other individual compounds from the extract i.e. harpagoside, 8-coumaroylhapagide and 
verbascoside individually produced greater inhibition than the crude extract of 
Harpagophytum procumbens. Our results as seen from figure 4.6 indicate that the crude 
extract produced greater inhibition than the individual components when comparing them at 
the same concentrations.  
When enzyme inhibition of harpagoside and harpagide were tested at 0.006 mg and 
0.002mg respectively which is the quantity that these compounds are represented in 0.2 mg 
of the extract, only 1% and 9% direct inhibition were demonstrated respectively. Similarly, 
Fiebich et al., (2001) reported no COX-2 inhibitory activity by harpagoside and harpagide in 
preventing the release of TNF-α synthase (a cytokine which is present during inflammatory 
conditions) at concentrations of up to 0.01mg.  
When the inhibitory effects of Harpagophytum procumbens extract, harpagoside and 
harpagide were observed clinically and in animal studies, differences also occurred with 
respect to whether the crude extract or individual components conferred greater inhibitory 
activity. 
Clinical studies revealed favourable results for the relief of various inflammatory conditions, 
which include osteoarthritis and back pain with Harpagophytum procumbens and 
harpagoside (Gagnier et al., 2004; Chrubasik et al., 2002; Chantre et al., 2000) when 
compared to other compounds such as diacerein and refocoxib. 
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Animal studies involving COX-2 inhibition by Harpagophytum procumbens extract indicated 
significant reduction in pain and inflammation induced by experimental test procedures 
(Anderson et al.,, 2004; Lanhers et al.,, 1992). These animal studies tend to indicate that 
compounds such as harpagoside do demonstrate anti-inflammatory properties (McGregor et 
al.,, 2005; Lanhers et al.,, 1992).  
The greater COX-2 direct inhibition exerted by the Harpagophytum procumbens extract 
compared to the combined inhibition of the harpagide and harpagoside may be as a result of 
other compounds in the extract. Gyurkovska et al., (2011) tested the inhibition (indirect) of 
COX-2 expression by crude extracts and components of Harpagophytum procumbens. It 
yielded strong inhibitory effects and suggested that the high activity is as a result of 
synergistic activity between the various components of the crude extract. It should be 
considered that crude extracts including Harpagophytum procumbens may contain a range 
of active compounds which all contribute to their efficacy which may not necessarily indicate 
synergy rather polyvalency (Williamson, 2001). 
Various studies reported differences in the activity of the crude extract with its constituents 
such as harpagoside and harpagide. However, what is generally observed is that the activity 
of the crude extract displayed better COX-2 inhibitory activity when compared to individual 
components.  
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5.3  Conclusion 
 
Harpagophytum procumbens extract produced direct inhibition of COX-2 enzyme, but less 
than the reference inhibitor DuP-697. COX-2 inhibition by Harpagophytum procumbens 
extract was greater than that of harpagoside and harpagide at the same concentrations. 
Harpagide had up to 12 times more inhibition activity as direct COX-2 enzyme inhibitor than 
harpagoside. The calculated combined inhibition of harpagoside and harpagide at the 
concentrations as they appear in the extract, is 10% compared to 68% by the 
Harpagophytum procumbens extract. However, the combination of these two components, 
with other compounds, which form part of the extract, has an even greater direct inhibition of 
COX-2 enzymes. This difference in COX-2 inhibition may be attributed to interplay 
expressed by other components in the extract. The IC50 values indicate that the 
Harpagophytum procumbens crude extract had the lowest IC50 concentration when 
compared to the harpagide and harpagoside. 
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CHAPTER SIX : Physiochemical properties 
 
The physicochemical properties of a drug substance are important determinants forthier 
permeation ability across the skin due to the barrier properties of the stratum corneum. 
These properties must to be understood when considering the mechanisms of permeation 
across the stratum corneum. The physiochemical properties of harpagide and harpagoside 
were determined and how these properties were affected by the presence of permeation 
enhancers and gel formulations. This provided an indication of permeation enhancer and gel 
formulations to use for permeation studies.  
6.1  Methods 
6.1.1  Physiochemical properties of harpagoside and    
  harpagide 
6.1.1.1 Determination of solubility of purified harpagoside and harpagide 
 
The aqueous solubility of harpagide and harpagoside in the crude extract Harpagophytum 
procumbens was determined by preparing solutions with increasing concentrations in 
phosphate buffer solution (PBS) at pH 7. The mixtures were stirred with a magnetic stirrer in 
a water-jacketed container at a 32°C for 24 hours. After 24 hours, solutions were filtered and 
analyzed by TLC for solubility determination. Maximum solubility was determined at the 
concentration where further addition of crude extract did not result in the increase in intensity 
of TLC spots with densitometric analysis. 
6.1.1.2 Experimental partition coefficient 
 
Partition coefficient experiments were performed with the marker compounds (harpagoside 
and harpagide) on its own; in the presence of permeation enhancers and gel formulation 
combinations.  
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The following method was used for determining the partition co-efficient. Test samples were 
added to pre-saturated PBS buffer, followed by mixing with pre-saturated n-octanol. This 
mixture was stoppered and agitated for 75 min followed by centrifuging at 4000 rpm for 45 
min resulting in the formation of two layers. Samples from the PBS layer were withdrawn 
from the mixture and analyzed by HPLC. It was filtered (0.45 µm) prior to being analyzed. 
The n-octanol-PBS partition coefficients (log D) were calculated as logarithmic ratios of the 
concentrations in the n-octanol phase to the concentrations in the PBS. The experiments 
were performed in triplicate.  
6.1.1.2.1 Preparation of pre-saturated n-octanol and PBS buffer 
 
Saturated n-octanol and PBS (pH 7) solutions were prepared by mixing equal volumes of 
these solvents together and shaking (Infors HT, Switzerland) for 24 hours. This was followed 
by separating the two-formed saturated layers from each other with a separating flask. 
6.1.1.2.2 n-octanol and PBS partitioning of the crude extract 
 
Partition co-efficient values for Harpagophytum procumbens crude extract were determined 
using the method described in 6.1.1.2. 
6.1.1.3 Gel Formulation 
The following gels were formulated: 
6.1.1.3.1 Pluronic® F-127 gel 
 
Distilled water was cooled to a temperature of 4°C in a refrigerator prior to adding to 2.5 g 
Pluronic® powder (BASF, Germany). The Pluronic® was sprinkled into distilled water (10 
ml) with constant agitation on a magnetic stirrer until it completely dissolved in a beaker. The 
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beaker was sealed with Parafilm® and refrigerated for 24 hours to aid dissolution and 
removal of air bubbles. 
6.1.1.3.2 Carbopol Ultrez 21®  
 
Three hundred milligrams of Carbopol Ultrez 21® (Lubrizol, USA) was sprinkled onto the 
surface of 10 ml distilled water in a beaker using a sieve to create an even fine sprinkle. This 
was gently stirred with a magnetic stirrer until it was completely dissolved. The beaker was 
sealed with Parafilm® and refrigerated for 24 hours to aid dissolution and removal of air 
bubbles. 
6.1.1.3.3 Hydroxypropyl cellulose 
 
Dispersed 250 milligram of hydroxypropyl cellulose in 3 ml ethanol on a magnetic stirrer at 
low speed in a beaker. Propylene glycol (2.8 ml) was added to the beaker followed by 3 ml 
distilled water. Stirring continued at low speed until gelling occurred. The beaker was sealed 
with Parafilm® and refrigerated for 24 hours to aid dissolution and removal of air bubbles.  
6.1.1.4 Partition co-efficient determination with various permeation  
  enhancers and gel formulations. 
6.1.1.4.1 n-octanol and PBS partitioning of harpagoside and harpagide in 
the crude extract with permeation enhancers. 
 
The enhancers SDS, DMSO, Cineole and Azone® were combined with the crude extract in 
separate containers. Each contained 7% permeation enhancer. The partition co-efficient 
values were determined using the method described in 6.1.1.2. 
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6.1.1.4.2 n-octanol and PBS partitioning of harpagoside and harpagide in 
the crude extract in gel formulations. 
 
The crude extract was added at a concentration of 300 mg/ml in each gel formulation 
(Carbopol Ultrez 21®, hydroxypropyl cellulose and Pluronic® F-127) and triturated until 
homogenous in beakers. Partition co-efficient values were determined using the method 
described in 6.1.1.2. 
6.1.1.4.3  n-octanol and PBS buffer partitioning of harpagoside and 
harpagide in the crude extract with gel formulations containing 
permeation enhancers. 
 
Each gel formulation containing crude drug was distributed into four beakers. The 
permeation enhancers namely, SDS, DMSO, Cineole and Azone® were slowly incorporated 
into the three formulated gels individually. The formulations contained 7% permeation 
enhancers. The literature indicates that, generally the concentration of the enhancers 
selected ranges between 5%-10%, it was therefore decided to use a 7% concentration in 
this study. Each beaker contained a different gel-enhancer combination. Partition co-efficient 
values were determined using the method described in 6.1.1.2. 
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6.2  Results and Discussion 
6.2.1  Aqueous Solubility 
 
Determining the solubility of individual components in crude extracts may be difficult as it 
contains many compounds with various properties and solubilities. In the case of 
Harpagophytum procumbens, it contains compounds such as iridiode glycosides, sugars, 
triterpenes, sterols, fats and waxes (Wichtl, 2004) that have varying degrees of aqueous 
solubility. No specific data is available for the solubility values of harpagoside and harpagide 
in various solvents including PBS. 
  Table 6.1 Aqueous solubility of harpagoside and harpagide   
   (Mean±SD, n=2). 
 
 
 
 
Table 6.1 represents the solubility of harpagoside and harpagide in PBS 7. These values 
may give an indication of how solubility will affect permeation across the stratum corneum. 
Harpagide has a higher solubility with a value of (58.6 mg/ml) when compared to 
harpagoside (30.3 mg/ml). Compounds with longer carbon chains tend to have decreased 
aqueous solubility as reported by Yano et al., 1986 investigating the skin permeability of 
various salicylates. The lower aqueous solubility of the harpagoside may also be associated 
with the carbon side chain attached to its O-ring structures, which may impart more lipophilic 
properties. This O-ring is absent in the harpagide. Gerber et al., (2006) suggests that 
compounds with aqueous solubility less than 1mg/ml may be problematic to permeate 
across the stratum corneum. Swart et al., 2005 reported when investigating the solubility of 
glycosides in an aqueous solvent (pH 7), that an increased transdermal permeation was 
Aqueous Solubility   
Harpagoside 30.3 mg/ml (0.8485) 
Harpagide 58.6 mg/ml (1.131) 
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observed when the aqueous solubility of the glycosides increased. Owing to the fact that our 
purified harpagoside and harpagide yielded aqueous solubility values more than 1mg/ml 
would suggest that the aqueous solubility of these compounds would not be the main 
restricting factor affecting transdermal permeation.  
6.2.2  Partition Co-efficient  
 
 The experimental octanol-PBS (pH 7) partition coefficient (Log D) values were determined. 
Higher Log D values indicate more lipophilic compounds. The Log D values of the 
harpagoside and harpagide in Harpagophytum procumbens extract were determined, as 
well as with gel formulations and permeation enhancers (SDS, DMSO, 1.8 Cineole and 
Azone®). The Log D value for the harpagoside present in the extract was calculated to be 
0.278 and -0.125 for harpagide. (table 6.2).  
Table 6.2 Log D values of harpagoside and harpagide from 
 crude extract (Mean±SD, n=3). 
 
 
 
 
The resultant higher Log D value for harpagoside compared to harpagide is what was 
expected, as the harpagide is more polar than the harpagoside as its chemical structure 
consists of a five-member ring with hydroxyl groups and a glycoside attached. The 
harpagoside has the same structure but has an unsaturated five-carbon chain with a 
benzene ring, which is more non-polar, and therefore, would likely increase lipophilic 
properties. 
Log D 
Harpagoside 0.278 (0.005) 
Harpagide - 0.125 (0.002) 
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  All the permeation enhancers tested decreased the Log D of harpagoside where Azone® 
produced the least reduction in log D (figure 6.1). DMSO resulted in the harpagoside shifting 
from a lipophilic value to a hydrophilic value of -0.111. 
Figure 6.1. Log D values for harpagoside and harpagide with    
various permeation enhancers (n=2). 
 
The harpagide presented a Log D value of -0.125. When enhancers were added to the 
crude extract, the Log D decreased except for Azone®.  
The terpene,1.8 Cineole  caused the biggest reduction in log D  (-0.352) for harpagide. The 
partition co-efficient of harpagoside, which has lipophilic properties, also displayed 
decreased Log D values in the presence of cineole even though cineole is lipophilic in nature  
(range of 2.6-2.8) (Copolovici and Niinemets, 2005). It is suggested that the activity of 
terpenes are dependent on the physiochemical properties of the penetrant and that the 
introduction of cineole may result in a decrease in the permeation of a penetrant (Sinha and 
Kaur, 2000; Gao and Singh, 1997). 
The Two Way analysis of variance (ANOVA) test indicated the partition co-efficient 
permeation enhancer data was statistically significant. The Tukey’s multiple comparison 
Crude
Extract
SDS DMSO Cineole Azone
Harpagoside 0.278 0 -0.111 0.079 0.252
Harpagide -0.125 -0.252 -0.158 -0.352 0.022
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post-test indicated that the changes in the log D values for harpagoside and harpagide in the 
presence of each of the permeation enhancers was statistically significant (P ≤ 0.05).  
Figure 6.2 represents the effect of various gel formulations on the partition co-efficient of 
harpagoside and harpagide. Hydroxypropyl cellulose gel formulation caused the highest 
increase in the log D value of harpagoside (0.313) which is higher than the log D value of the 
harpagoside component on its own 0.278. The Pluronic® F-127 hydrogel formulation 
decreased the log D value of harpagoside (- 0.193). 
        Figure 6.2. Log D values for hapagoside and harpagide with gel formulations (n=2). 
 
All the gel formulations increased the log D values of harpagide; with the Carbopol Ultrez 
21® producing the largest increase to the lipophilic region. 
The extent to which the harpagoside partitioned with the gels may be related to the 
excipients used in the different formulations.  The hydroxypropyl cellulose gel consists of 
ethanol, water and polypropylene glycol, which has good gelling properties and allows for 
the incorporation of permeation enhancers (Janathraprapapa and Stagni, 2007). This gel 
formulation consisted of the lowest water concentration when compared to the other two 
formulations. It resulted in a higher Log D value for harpagoside. The presence of ethanol 
Crude Extract
Hydroxypropyl
cellulose
Carbopol Pluronic
Harpagoside 0.278 0.313 0.252 -0.193
Harpagide -0.125 -0.067 0.112 -0.022
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may also have contributed as it has non-polar properties imparting more lipophilic 
tendencies. 
 The Carbopol Ultrez 21® consists of hydrophobically modified cross-linked polyacrylate 
polymers (Lubrizol, USA) which may have resulted in partitioning of harpagoside and 
harpagide in the lipophilic region even though it had a high water content in its formulation.  
The permeation enhancer that produced the least favourable Log D results was excluded 
from this study. This was cineole as it reduced harpagide Log D value further from the 
recommended 1-2 Log D value for transdermal permeation (Gerber et al., 2006).  
Various combinations of the remaining permeation enhancers and gel formulations were 
tested in order to determine the effect on the partition coefficient values of harpagoside and 
harpagide. 
Figure 6.3 represents the log D values of harpagoside and harpagide with SDS when 
incorporated into the 3 different gel formulations. Its combination with hydroxypropyl 
cellulose reveals a log D value of 0.578 for harpagoside, which is almost double the value 
when compared to the log D value of the harpagoside only (without the presence of an 
enhancer or gel formulation). This SDS hydroxypropyl cellulose value is also higher than the 
log D value of harpagoside when combined with hydroxypropyl cellulose Gel Only 
combination (0.313) (figure 6.2). 
The combination of the SDS Pluronic® Gel formulation increased the Log D of harpagoside 
(0.235) compared to Pluronic® Gel only (-0.191). However, this value was still less than the 
log D value of harpagoside when no enhancer or gel was incorporated. 
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Figure 6.3 Log D values of harpagoside and harpagide with gel formulations 
containing SDS (n=2). 
  
All 3 gel formulations containing SDS resulted in an increase in Log D of harpagide. 
Hydroxypropyl cellulose and Carbopol Ultrez 21® formulations with SDS increased the log D 
values of harpagoside and harpagide more than the values of these compounds when 
tested as an extract only (without permeation enhancer or gel). All changes in Log D values 
for harpagoside and harpagide with SDS and the various gel formulations were deemed 
statistically significant (P ≤ 0.05). 
Figure 6.4 represents the resultant log D values of harpagoside and harpagide when the 
permeation enhancer Azone® was incorporated in the 3 gel formulations. The Azone® 
hydroxypropyl cellulose combination yielded higher Log D values than when harpagoside 
and harpagide were combined with Azone® (figure 6.1) and hydroxypropyl cellulose gel 
(figure 6.2) alone. The combination of Azone® with the hydroxypropyl cellulose gel 
increased Log D of harpagoside and harpagide with values of 0.359 and 0.252 respectively, 
both statistically significant (P ≤ 0.05).  
Jantharaprapapa and Stagni (2007) suggested that a higher solubility of a compound in a 
vehicle (gel) lowers the chemical potential of the permeation enhancer, which results in a 
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decrease in Log D. This could explain why the harpagide log D value is lower when Azone® 
was incorporated into the Carbopol Ultrez 21® formulation, suggesting good solubility 
between harpagide and aqueous based Carbopol Ultrez 21®. 
Figure 6.4 Log D values of harpagoside and harpagide with gel formulations 
containing Azone® (n=2). . 
 
 
The Pluronic® and Carbopol Ultrez 21® gels when formulated with Azone® resulted in log D 
values lower than when harpagoside and harpagide were tested without enhancers or gels 
.The Log D value for harpagide with the Azone® Carbopol Ultrez 21® gel resulted in the 
biggest decrease when compared to other gel combinations.  
All gel combinations with DMSO resulted in decreased lipophilicity of harpagoside (figure 
6.5). When DMSO was incorporated into the gel formulations harpagide had the largest in  
log D (0.352) with the Carbopol Ultrez 21® gel, followed by the Pluronic® gel, both 
statistically significant (P ≤ 0.05) compared to the crude extract only value. 
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Figure 6.5 Log D values of harpagoside and harpagide with gel formulations 
 containing DMSO (n=2).
 
 
 
All DMSO gel formulations resulted in log D values of harpagoside and harpagide being 
higher compared to the DMSO crude extract only combination tested in figure 6.1. 
For harpagoside, the hydroxypropyl cellulose formulated with SDS yielded the highest log D 
value of 0.578. This was followed by the hydroxypropyl cellulose and Azone® gel with a log 
D value of 0.359. 
The highest log D value (0.406) for harpagide was obtained with the combination of the 
Carbopol Ultrez 21® containing SDS. This was followed by a value of 0.35 which was 
obtained by 3 different gel – enhancer combinations namely, hydroxypropyl cellulose with 
SDS; Pluronic® with SDS and Carbopol Ultrez 21® with DMSO. 
The hydroxypropyl cellulose gel with Azone® and hydroxypropyl SDS formulations yielded 
the highest Log D values for harpagoside as well as increasing the log D value of harpagide 
when compared to the crude extract log D value on its own (i.e. no enhancer or gel 
formulation).  Ghafourian et al., 2004 suggests that increased log D values of certain 
enhancer-gel formulations may be as a result of synergy between these excipients.  
Crude Extract
Hydroxypropyl
cellulose DMSO
Carbopol DMSO Pluronic DMSO
Harpagoside 0.278 0.243 0.193 0.087
Harpagide -0.125 0.158 0.352 0.252
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The Carbopol Ultrez 21® - SDS formulation was not selected for permeation experiments 
even though it yielded the highest harpagide log D value. The reason for its omission is that 
the corresponding harpagoside log D value was less than the crude extract on its own (i.e. 
no enhancer or gel formulation). DMSO was the second permeation enhancer excluded as it 
reduced the harpagoside and harpagide into the hydrophilic range and further, from the log 
D 1-2 range, Pluronic® was the gel formulation excluded, as it caused the largest reduction 
of log D for harpagoside. 
The properties of penetrants includes the extent of its ionization and its ability to form ion 
complexes in the presence of other compounds which impact on its partitioning to either the 
aqueous or lipophilic phase in a system (Inagi et al., 1980). It could be considered that the 
permeation enhancers may play a part in the ion complex formation of penetrants to affect 
its partitioning ability. Considering that the skin is comprised of lipophilic and hydrophilic 
regions, the compound permeating across it should have properties demonstrating some 
affinity for both regions (Sloan et al., 2006; Kalia et al., 2001). It is therefore, suggested that 
log D values required for good compound permeability are in the range of 1-2 coupled with 
an aqueous solubility of more than 1mg/ml (Gerber et al., 2006; Naik et al., 2000). The aim 
is to formulate a gel preparation with an enhancer to get as close as possible to these 
values. However, combinations of higher or lower solubility and log D values may ultimately 
affect the flux values obtained by compounds across the skin as demonstrated by Gerber et 
al., 2006. This together with the action of the selected gel formulation and enhancers on the 
skin may play a significant role in increasing the flux values of harpagoside and harpagide. 
In order to perform the permeation studies with synthetic membranes using Franz diffusional 
cells, one gel formulation (hydroxypropyl cellulose) with 2 enhancer (Azone®, SDS) 
combinations were selected.  Combinations were selected based on increasing lipophilicity 
achieved by the gels and enhancer combinations. 
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6.3  Conclusion 
 
Harpagoside displayed a higher Log D (0.278) value, when compared to harpagide (-0.125). 
Harpagoside (30.3 mg/ml) and harpagide (58.6 mg/ml) displayed aqueous solubility values 
above the 1mg/ml.  
Hydroxypropyl cellulose gel formulation caused the highest increase in the log D value of 
harpagoside (0.313) which is higher than the log D value of the harpagoside component on 
its own 0.278. All the gel formulations increased the log D values of harpagide with Carbopol 
Ultrez 21® producing the largest increase. 
All 3 gel types containing SDS resulted in an increase in the Log D of harpagide. The 
combination of Azone® with the hydroxypropyl cellulose gel increased the Log D values of 
harpagoside and harpagide to 0.359 and 0.252 respectively. All gel combinations with 
DMSO resulted in decreased Log D of harpagoside. 
Hydroxypropyl cellulose containing Azone® and hydroxypropyl cellulose containing SDS 
were the gel formulation combinations selected for permeation studies. These formulations 
yielded log D values between 0-1 for harpagoside and harpagide. 
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CHAPTER SEVEN Permeation studies 
 
7.1  Synthetic membranes 
 
Permeation studies were performed with the selected gel-enhancer formulations 
(hydroxypropyl cellulose gel containing 300 mg/ml crude extract and 7% permeation 
enhancers, either Azone® or SDS) on synthetic membranes namely Sil-Tec ® (hydrophobic 
properties) and Tuffyrn® (hydrophilic properties). This was performed in order to determine 
the permeation profile of harpagoside and harpagide in a gel formulation (with and without 
enhancers). Plotting the average cumulative amount per area versus time represented an 
indication of the release characteristics and flux of the two marker compounds from the 
various gel formulations. These experiments were performed prior to transdermal 
permeation studies using human skin samples. 
7.1.1 Methods 
7.1.1.1 Synthetic membrane preparation 
 
The membranes selected for permeation studies for the synthetic membrane experiments 
were Sil-Tec® (hydrophobic properties) and Tuffyrn® (hydrophilic properties). Prior to 
placement into Franz diffusion cells, the membranes were rinsed by soaking it in a PBS 
buffer solution for 10 minutes, placed on Whatman® filter paper and allowed to air dry. 
7.1.1.2 Franz diffusion cell 
 
Vertical Franz diffusion cells with 2.0 ml receptor compartments and 1.0751cm2 effective 
diffusion area were used for the permeation studies (figure 7.1). A stirrer bar was placed in 
the receptor solution cavity of the bottom section of the Franz diffusional cell. The membrane 
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was carefully mounted on the bottom section of the Franz cell. The two sections of the Franz 
cells were attached. Vacuum grease was applied to the circumference in order to prevent 
leakage of the cells. A spring loaded U clamp was used to tighten the upper and lower parts 
of the Franz cell with the membrane separating the donor and receptor compartments of the 
Franz cell. 
  Figure 7.1 Franz diffusional cell with U – clamp 
 
 
 The receptor compartments were filled with 2 ml isotonic PBS (pH 7.4). This was gently 
introduced with tubing attached to a syringe to prevent air bubbles from being introduced 
into the receptor compartment that usually settles at the membrane causing a reduction in 
surface area. The donor compartment was filled with 1 ml of the test sample and covered 
with Parafilm® to prevent evaporation of components within the sample for the duration of 
the experiment. An excess amount of sample was present in the donor compartments at all 
times during the experiments. The Franz cells were placed in a water bath onto specifically 
moulded holders, which allow for only the receptor compartment to be exposed to the water 
(37°C) circulating in the water bath. The base of the water bath was fitted with a multi stage 
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magnetic stirrer. The entire volume of the receptor was withdrawn from each Franz cell and 
replaced with fresh PBS buffer preheated at 37°C with the aid of tubing attached to a 
syringe. Each Franz cell had its own set of tubing and syringes. Receptor compartment 
withdrawal and replacement occurred after 2, 4, 6, 8, 10 and 12 hours. The experiments 
were conducted over a 12 hour period. 
7.1.1.3 Donor formulations 
 
The donor compartment of the Franz diffusional cells was filled with the different gel 
formulations. The top of the donor compartment was closed with Parafilm® to prevent 
possible loss during experimentation. 
7.1.1.4 Solid Phase Extraction 
 
 Samples taken from the receptor compartment had to be concentrated prior to analysis. For 
this purpose, solid phase extraction of the solutes was performed. The solid phase 
extraction parameters with respect to flow rate, solvent system and column bonding phase 
type was determined using the Phenomenex® Strata® preparation method development 
software version 1.  A Strata®-X 30mg/1ml 8B-S100-TAK solid phase, polymeric RP sorbent 
extraction column was selected. Solid phase extraction flow rates of 3-6ml/min were used. 
The solid phase extraction cartridge was conditioned with 1ml methanol for 10-20 seconds 
followed by washing with 1ml distilled water for 10-20 seconds. The sample (the contents of 
the receptor compartment of each Franz cell at each time interval) was loaded to the 
cartridge with a flow rate for 1-2ml/min and washed with 1ml water with a flow rate between 
1-2ml/min. 
The cartridge was dried under vacuum for 1 minute and then eluted with 1ml 
methanol/acetonitrile (1:1) solution. The elution solvent was allowed to soak into the sorbent 
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for 60 seconds and eluted using a flow rate of between to 1-2ml/min. New cartridges were 
used for each sample. 
 The elution solvent was removed and transferred to 2 ml Greiner® vials and placed in a 
digital dry bath, set at a temperature of 37º C under a gentle stream of nitrogen through a 
manifold. The contents were reconstituted with methanol. 
7.1.1.5 Determination of Flux 
 
The samples were assayed by HPLC for quantification. The mean flux of harpagoside and 
harpagide was calculated by plotting the average cumulative amount of marker compound 
(in receptor compartment) per area versus time. The slope of the linear portion of the curve 
represents the average (mean) flux value. Data was fitted into GraphPad Prism® version 5 
software for steady state curve and flux value extrapolation.  
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7.1.2 Results and Discussion  
7.1.2.1 Flux Values 
 
Figure 7.2 represents the cumulative quantities of harpagide that permeated through the 
hydrophobic synthetic Sil-Tec® membrane over a 12 hour period with 3 gel formulations, 2 
of which contained the permeation enhancers.  
 
Figure 7.2 Cumulative amount per unit area of harpagide in various formulations  
per unit area that penetrated through Sil-Tec® vs. time. 
 
 
The average value of the slope of the linear segment of the graph above was used to 
determine the flux value (figure 7.3). Flux values for all permeation studies with Sil-Tec® and 
Tuffyrn® membranes were determined in this manner (annexure II and III). 
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Figure 7.3 The average cumulative amount of harpagide that 
penetrated Sil-Tec®  with the Gel only formulation as a function 
of time (n=2). 
 
The solubility test of the harpagoside and harpagide demonstrated that PBS as receptor fluid 
is not a rate-limiting step in this permeation process as the maximum solubility concentration 
was not reached in the receptor solution of the Franz cells. Solubility limitations did not 
influence the values obtained for the various formulations.  
7.1.2.2 Synthetic hydrophobic membrane (Sil-Tec®) and hydrophilic 
membrane (Tuffyrn®). 
 
The flux values of harpagoside and harpagide in the 3 gel formulations where compared 
after permeating across the hydrophobic synthetic Sil-Tec® membrane. The gel formulation 
consisting of the permeation enhancer Azone® increased the flux value of harpagoside to 
374.3 µg/cm² (Table 7.1) compared the gel formulation without any enhancers (27.1 µg/cm²) 
which was statistically significant (P ≤ 0.05). 
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Table 7.1 Flux values and enhancement ratio (ER) of harpagoside with various gel 
formulations permeating through the hydrophobic Sil-Tec® membrane( Mean±SD, n=2). 
Hydrophobic  membrane  
(Sil-Tec®)– Harpagoside 
Flux (µg.cm-2.h-1) Enhancement ratio (ER) 
Gel only 27.1 (1.3)  
Gel + Azone® 374.3 (44.5) 13.9 
Gel  + SDS 3.9 (0) 0.1 
 
The Azone formulation resulted in an enhancement ratio of 13.9. Conversely, the SDS 
formulation decreased the flux value of harpagoside to 3.9 µg.cm-2.h-1. When comparing the 
flux values of harpagide across the Sil-Tec® membrane (table 7.2), the flux values obtained 
for the Azone® gel (150 (µg.cm-2.h-1) was similar to that of the Gel only formulation (156 
(µg.cm-2.h-1). 
Table 7.2 Flux values and enhancement ratio (ER) of harpagide and with various gel 
formulations permeating through the hydrophobic Sil-Tec® membrane (Mean±SD, n=2). 
 
Hydrophobic  membrane 
(Sil-Tec®) – Harpagide 
Flux (µg.cm-2.h-1) Enhancement ratio (ER) 
Gel only 156 (10.6)  
Gel + Azone® 150 (18.3) 1 
Gel  + SDS 46.2 (1.6) 0.3 
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The SDS Gel decreased the flux of harpagide resulting in a value of 46.2 µg.cm-2.h-1. This 
reduction is similar to the SDS gel reducing the flux value of harpagoside, when compared to 
the Gel only formulation (figure 7.4).  
Harpagide flux values were higher than harpagoside for the Gel only formulation as well as 
the SDS gel formulation. The only increase in flux achieved with this Sil-Tec® was with the 
Azone® Gel formulation which increased the flux value of harpagoside.  
 
Figure 7.4 Flux values of harpagide and harpagoside with various gel 
formulations permeating through Sil-Tec® membrane (n=2). 
  
 
The flux value for harpagoside permeating across the synthetic hydrophilic Tuffyrn® 
membrane was 537 µg.cm-2.h-1 for the Gel only formulation as seen in table 7.3. When the 
flux values of this formulation was compared to formulations containing Azone® and SDS 
the values decreased resulting in enhancement ratios of less than 1. Azone® gel 
demonstrated the greatest decrease in the reduction of flux  (90.1 (µg.cm-2.h-1) when 
compared to the Gel only sample. 
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Table 7.3 Flux values and enhancement ratio (ER) of harpagoside with various gel 
formulations permeating through the hydrophilic Tuffyrn® membrane (Mean±SD, n=2). 
Hydrophilic  membrane 
(Tuffyrn®) – Harpagoside 
Flux (µg.cm-2.h-1) Enhancement Ratio (ER) 
Gel only 537.1 (33.2)  
Gel + Azone® 90.1 (1.3) 0.2 
Gel  + SDS 217.4 (4.2) 0.4 
 
 The SDS gel formulation increased the flux value of harpagide to 144.8 µg.cm-2.h-1 across 
the Tuffyrn® membrane (table 7.4.) Incorporation of Azone® into the formulation resulted in 
harpagide content not being detected in the receptor compartment of the Franz cell (This 
experiment was repeated for verification and yielded the same result), indicating that the flux 
value of the Azone® formulation was less than that of the Gel only formulation.  
 
Table 7.4 Flux values and enhancement ratio (ER) of harpagide and with various gel 
formulations permeating through the hydrophilic Tuffyrn® membrane. (Mean±SD, n=2) 
Hydrophilic  membrane 
(Tuffyrn®) – Harpagide 
Flux (µg.cm-2.h-1) 
 
Enhancement Ratio (ER) 
Gel only 101.1 (0.7)  
Gel + Azone® - - 
Gel  + SDS 144.8 (0.21) 1.4 
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The flux value of harpagide in SDS Gel with this Tuffyrn® membrane was the only flux value 
more than its respective Gel only formulation (Figure 7.5).  
Figure 7.5 Flux values of harpagide and harpagoside with various gel 
formulations permeating through Tuffyrn® membrane (n=2). 
 
 
When observing flux values of harpagoside for the Gel only formulations the results indicate 
that the hydrophilic membrane produced higher flux values compared to the lipophilic 
membrane. This result is similar to Clement et al. (2000) who reported that caffeine with a 
log D value of -0.1 displayed higher flux values through a hydrophilic  (633 µg.cm-2.h-1) 
polysulphane membrane compared to the lipophilic silicone membrane (9.5 (µg.cm-2.h-1). A 
factor contributing to the lower permeation in the lipophilic membrane is that the formulation 
used in the Clement et al., (2000) study was an alcohol based gel with hydrophilic properties 
and therefore, possibly had less affinity for the lipophilic membrane as suggested by the 
authors. Further, our Gel formulation is also a hydro-alcoholic base, making it to have more 
hydrophilic properties possibly contributing to higher permeation in the hydrophilic 
membrane as observed.  
The permeation enhancers also displayed an effect on the flux of the marker compounds 
across both synthetic membranes as the flux values differed when compared to the Gel only 
formulation. This could be due to the interaction of the enhancer on the active compound or 
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gel formulation as well as possible interaction with the membranes. Azone® has surfactant 
properties, enhancing wetting of the gel on the surface of the synthetic membranes which 
leads to increased flux values as suggested by Ferreira et al., (1994). They suggested that 
an emulsion formulation containing a surfactant had better permeation compared to an 
aqueous solution due to better wetting, resulting in better contact. This suggests that 
increases in flux rates for both membrane types with Azone® could be expected and not 
only for the hydrophobic membrane. However, the effect of the permeation enhancers in the 
gel formulation did not produce a large increase in the enhancement ratio across both 
membranes except for harpagoside with Azone® on the Sil-Tec® membrane. 
 When SDS, which has good surfactant properties, was incorporated into the formulation a 
general decrease in flux was observed. Despite permeation enhancers providing wetting 
properties to the membranes, other factors resulted in decreased flux rates. The efficacy of 
compounds such as SDS in the reduction of surface tension for better wetting can be 
affected by formulation excipients including the penetrant (Boulenc et al., 1995). The 
excipients present in the formulation may affect the physical integrity of the membrane or the 
active compound may bind to the membrane (Thakker and Chern 2003). This could explain 
the general reduction in permeation in the presence of SDS in the formulation. 
Permeation enhancers may also affect the electronic charge potential of the marker 
compounds which may promote or hinder permeation as compounds may prefer to 
permeate a membrane as ion pairs making it more or less polar. This was reported by 
Tantishaiyakul et al., (2004), where benzoate permeated through a silicone membrane 
preferentially as an ion pair rather than a single ion. Therefore, compounds related to good 
wetting properties may not necessarily increase the rate of permeation as other factors may 
override the effect of surfactant properties of the permeation enhancers. 
Due to the hydrophobic nature of the Sil-Tec® synthetic membrane, it would be expected 
that hydrophobic compounds would have higher flux rates than hydrophilic compounds. Our 
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partition coefficient results indicate that harpagoside is more hydrophobic than harpagide. 
Yet the flux value of harpagide with the Gel only formulation which permeated across the 
hydrophobic Sil-Tec® membrane was higher than harpagoside. Conversely, the hydrophilic 
Tuffyrn® membrane yielded a higher flux value for harpagoside than harpagide with the 
same Gel only formulation. Although lipophilicity is an important factor to consider in 
determining the permeation potential of compounds across membranes, other factors also 
contribute to this process. These include molecular weight and size as well as chemical 
composition and orientation. Gel formulation excipients including permeation enhancers 
influence these factors resulting in differing permeation rates between compounds as can be 
seen by the action of the Azone® and SDS. 
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7.1.3 Conclusion 
 
The permeation enhancer used in the formulation and the nature of the synthetic 
membranes affected the harpagoside and harpagide permeation profile. For harpagide, all 
flux values decreased when permeation enhancers were added except for the SDS Gel with 
the Tuffryn® membrane. For harpagoside, Azone® Gel on the Sil-Tec® membrane showed 
higher flux values. 
The role of the permeation enhancer on the flux value may be due to it affecting the release 
from the gel and influencing the availability of harpagoside and harpagide at the surface of 
the synthetic membrane or the membrane could be the rate-limiting step. Harpagide and 
harpagoside responded differently with respect to flux values obtained in the presence of 
permeation enhancers. The flux value of harpagide in the Gel only formulation that 
permeated across the hydrophobic Sil-Tec® membrane was higher than that of harpagoside 
and the hydrophilic Tuffyrn® membrane yielded a higher flux value for harpagoside than 
harpagide with the same Gel only formulation.  Generally, no direct distinction can be made 
that would indicate that one of the membranes had higher rates of permeation over the 
other. The results do suggest that the marker compounds are being released from the 
formulations albeit to varying degrees.  
Following the determination that harpagoside and harpagide have diffused from the gel 
dosage form and permeated across the membrane with the various formulated gels, 
transdermal permeation experimental studies were performed with human skin. The 
formulations included the Gel only formulation as well as gel formulations consisting of 
Azone® and SDS. 
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7.2  Transdermal permeation 
7.2.1  Methods 
 
Transdermal permeation studies were performed with the selected gel-enhancer 
formulations (hydroxypropyl cellulose gel containing 300 mg/ml crude extract and 7% 
permeation enhancers, either Azone® or SDS) as with synthetic membranes. The same 
apparatus and methods were used for transdermal permeation studies as used for the 
synthetic membranes. This included the Franz diffusional cells with PBS pH 7.4 receptor 
solutions with a multi stage magnetic stirrer in a water bath at 37°C. The samples were 
withdrawn and replaced at 2 hour intervals for 12 hours. This was followed by solid phase 
extraction of the sample in the receptor solution. For transdermal permeation studies, human 
epidermal skin was used. 
 7.2.1.1 Human skin membrane preparation 
 
Female human abdominal skin was used for the transdermal permeation studies. Skin 
samples were obtained from abdominoplasty surgical procedures performed by plastic 
surgeons. Samples were maintained under cold chain conditions during transportation from 
the hospital to the University. Ethics approval was obtained from the Ethics Committee of 
University of the Western Cape (ethics approval number 09/7/40). Patient medical records 
were not accessed and patient confidentiality was maintained. The specimens received 
contained full thickness skin, which included the all skin layers including the fatty hypodermis 
with a thickness of about 7 cm. A sharp knife, scalpel and forceps were used to carefully 
separate the fatty hypodermis resulting in only the full thickness skin with the epidermis as 
seen in figure 7.6. 
Following the removal of the fatty hypodermis, the stratum corneum was removed by first 
immersing the full thickness skin in 60°C HPLC water for 1 minute. A glass plate used during 
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the removal of the stratum corneum was maintained at a temperature of 37°C with 
circulating water. The epidermis was gently teased away from the skin with forceps and 
scalpel. Special care was taken that the integrity of the thin delicate stratum corneum was 
not compromised. 
Figure 7.6 Full thickness human abdominal skin after hypodermis removal. 
 
 
It was placed in a shallow container with HPLC grade water and carefully placed on 
Whatman® filter paper. The water was drained from the container with a syringe resulting in 
the stratum corneum distributing uniformly on the filter paper (figure 7.7) 
The stratum corneum was sealed in foil, stored in a designated freezer at -20ºC. All 
biological waste material was disposed in a bio hazardous container and removed weekly by 
designated contractors. Prior to use, the stratum corneum was thawed and examined 
visually with the aid of a colony plate reader due to its magnification and lighting abilities, for 
any defects, before it was mounted on the Franz diffusion cells. 
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Figure 7.7 Stratum corneum after the removal of the dermal layers drained on 
Whatman® filter paper. 
 
 
The same Franz diffusional method and donor solutions used with the synthetic membrane 
were applied to the transdermal permeation study. The stratum corneum was carefully 
mounted to the receptor compartment of the Franz cell with the external side of the stratum 
corneum facing upward. Silicone grease was applied on the edges of the donor and receptor 
compartment of the Franz cells. These compartments were clamped together with a U- 
clamp to hold the cells in place. Samples were inserted into the donor compartment of the 
Franz cells. 
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7.2.2  Results and discussion 
7.2.2.1 Flux values 
 
The mean flux of harpagoside and harpagide permeating through the human skin was 
calculated by plotting the average cumulative amount per area versus time. The slope of the 
linear portion of the curve represents the average (mean) flux value. Figure 7.8 represents 
the cumulative 2 hourly readings of the Franz cells for harpagoside with the Gel Only 
formulation. 
Figure 7.8 The cumulative amount of harpagoside per area in each Franz cell 
permeating the skin as a function of time. 
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The average cumulative concentration curve reading was used to determine the flux value 
as seen in figure 7.9 .The average flux value for harpagoside and harpagide with the various 
gel formulations were calculated in the same manner (plotting the average cumulative 
amount per area versus time- annexure IV) 
Figure 7.9 The average cumulative amount of harpagoside,               
which permeated the skin as a function of time to illustrate                   
average flux for harpagoside (n=4).
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The changes in flux values across the human stratum corneum upon addition of permeation 
enhancers Azone® and SDS in our study are listed for harpagoside in table 7.5. The gel 
formulation consisting of the Azone® yielded an enhancement ratio of 14 when compared to 
the Gel only formulation (statistically significant P ≤0.05).  The SDS Gel formulation (14.16 
µg.cm-2.h-1) yielded the lowest value, even less than the Gel only formulation (18.4 µg.cm-2.h-
1). 
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Table 7.5 Average flux and enhancement ratio for harpagoside with various gel 
formulations. (Mean±SD, n=4). 
Human epidermis– 
Harpagoside 
Flux (µg.cm-2.h-1) Enhancement ratio (ER) 
Gel only 18.4 (1.9)  
Gel + Azone® 256.8 (54.6) 14 
Gel  + SDS 14.1 (1.9) 0.8 
 
The gel formulation consisting of Azone® also yielded the highest flux value with an 
enhancement ratio of 8 when compared to the Gel only formulation for harpagide (table 7.6). 
Diez-Sales et al. (1996) who investigated the effect of enhancers on skin permeation 
reported that Azone produced increased transdermal permeation of various compounds 
ranging from hydrophilic to lipophilic across human skin. Niazy (1996) also demonstrated 
that  Azone® increased skin permeation of dihyroergotamine across the human skin 55 
times compared to a formulation not containing Azone®. Similarly, Degim et al., (1999) 
reported that Azone® resulted in a 3-fold increase of naproxen through human skin after 
pretreatment of the skin with Azone®. The gel formulation consisting of Azone® yielded the 
best permeation results for harpagoside and harpagide compounds. 
Table 7.6 Average flux and enhancement ratio for harpagide with various gel 
formulations. (Mean±SD, n=4). 
Human epidermis– Harpagide Flux (µg.cm-2.h-1) Enhancement ratio (ER) 
Gel only 5.05 (0.6)  
Gel + Azone® 38.7 (1.2) 8 
Gel  + SDS 36.4 (8.5) 7 
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The SDS gel formulation yielded a result with an enhancement ratio of 7 for the harpagide 
compound compared to the gel only formulation. The difference between these 2 
formulations was not statistically significant. The SDS Gel formulation resulted in a decrease 
in the flux value compared to the Gel only formulation and an enhancement ratio of less than 
1 for harpagoside. The mechanism of permeation enhancement by SDS could be attributed 
to the insertions and disruption of the bilayer of the stratum corneum (Ribuad et al., 1994). 
Borra-Blasco et al. 1997 reported when assessing the permeation of four different 
compounds with varying lipophicities that the effect of SDS decreases as the lipophilicity of 
the compounds increases. Similarly, Copovi (2006) indicated that SDS had no effect on 
compounds with a log P value of more than 3 and the most hydrophilic compound (log P -
0.95) tested 5-flourouracil, displayed the largest enhancement ratio. The difference in the 
enhancement ratio between harpagoside and harpagide in the presence of SDS may also 
be due to SDS affecting the polarity of the stratum corneum because hydrophobic interaction 
of the SDS alkyl chain with the skin structure would leave the end sulphate group of the SDS 
compound exposed, this would create more sites in the membrane which could allow polar 
molecules to partition across the stratum corneum more easily (Borra-Blasco et al., 1997). 
The solvents and co-solvents in the gel formulation selected consist of ethanol, propylene 
glycol and water (1:1:1), as used by Janathraprapapa and Stagni (2007) who demonstrated 
that this formulation allowed for the addition of various permeation enhancers and 
contributed to the permeation of compounds across a synthetic membrane. The ethanol and 
propylene glycol in this formulation may also contribute towards an increase in the flux value 
of the compounds. However, a maximum concentration should be considered as the various 
formulations tested in the Janathraprapapa and Stagni (2007) study indicated that high 
concentrations of ethanol and propylene glycol in the gel formulation decreased the 
permeation profile values and an ideal seems to be equal quantities of the co-solvents i.e. 
ethanol, propylene glycol and water.  The increase in the concentration of the co-solvent 
propylene glycol beyond 30% may result in a decrease in flux as demonstrated by Thomas 
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and Panchagula (2003) when testing various concentrations of propylene glycol with AZT 
permeation across rat epidermis. 
Ethanol is an effective solvent for polar and non polar groups of structures and it is feasible 
that small quantities are capable of leaching significant quantities of non-covalently bound 
amphophilic stratum corneum lipids which would affect the skin barrier and act as 
permeation enhancer (Heard et al., 2006). At lower concentrations, ethanol (30%) may 
increase the lipid fluidity of the stratum corneum at polar interfaces (Suhonen et al., 1999), 
which could result in increased flux values of compounds in formulations. Water as a co-
solvent may as a result of its polar nature interact with the polar head groups of lipids in 
stratum corneum, upsetting the packing nature of the polar arrangement (Suhonen et al., 
1999), therefore promoting permeation. Hydrophilic tendencies of ethanol and propylene 
glycol may also increase the hydrophilic properties of the gel formulation favouring the 
harpagide more than harpagoside.  
7.2.2.2 Solubility and Molecular weight vs. flux 
 
When comparing the Gel only flux values of the two marker compounds with their relative 
solubilities, the harpagoside with the lower aqueous solubility of the 2 marker compounds 
displayed the highest permeation across the human skin for the Gel only and the Azone® 
gel preparation (table 7.7). It also displayed the largest ER with Azone® Gel when compared 
to harpagide.  
Harpagoside which has a higher molecular weight compared to harpagide displayed the 
higher flux reading than with the Gel only formulation. Higher molecular weight compounds 
are usually associated with the lower flux values (Malan SF et al., 2002). The volume that 
the compounds occupy in their structural orientation should also be considered. Compounds 
with a molecular weight less than 500 Dalton are considered good candidates for 
transdermal permeation (Bos and Meinardi 2000). 
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Table 7.7. Physiological properties of harpagoside and harpagide compared to the 
flux values of the various gel formulations. 
Compound Molecular 
Weight (mg) 
Solubility 
(mg/m)l 
Flux – Gel  
(µg.cm-2.h-1) 
Flux- Azone® 
(µg.cm-2.h-1) 
Flux-SDS 
(µg.cm-2.h-1) 
Harpagoside 494.5 30.3 mg/ml 18.41 256.8 14.16 
Harpagide 364.3 58.6 mg/ml 5.05 38.7 36.4 
 
7.2.2.3 Partition Co-efficient vs. flux 
 
Figure 7.10 demonstrates that formulations, which produced higher partition co-efficient 
values for harpagide, resulted in higher flux values, where the gel formulation consisting of 
SDS had the highest log D and flux. 
 
Figure 7.10 The relationship between flux and partition 
 co-efficient of different gel formulations for  harpagide. 
 
For harpagoside, increased flux values were obtained upon addition of the Azone® and SDS 
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largest increase in the flux value even though it had a lower log D value (0.359) when 
compared to the SDS gel formulation (0.578)  
The SDS gel formulation did not increase the flux value of harpagoside with an increase in 
the log D value when compared to the Gel only formulation. Its flux value was less than that 
of the Gel only formulation even though the log D value increased. 
The suggested partition co-efficient value for compounds to be used for transdermal 
permeation should be between 1-2 (Gerber et al., 2006). This range offers a better chance 
of permeation across the various skin layers such as the more hydrophobic stratum corneum 
and the hydrophilic lipid bilayer (Bos and Meinardi 2000). 
 
       Figure 7.11 The relationship between flux and 
       partition co-efficient of different gel formulations  
       for harpagoside. 
 
 
 
When the relationship between the physiochemical properties of the Gel only formulation 
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greater impact on the increase in the flux value on the compound with lower aqueous 
solubility i.e. harpagoside, with an ER = 14 compared to the more aqueous soluble 
harpagide, compound (ER = 8). Harpagoside also had a higher log D value than harpagide. 
The addition of SDS to the gel formulation resulted in a decrease in flux for harpagoside and 
an increase for harpagide.  
When assessing the physiochemical properties of harpagoside and harpagide no clear 
pattern emerges that would indicate how these properties affect the flux values. The 
permeation enhancers, however, do seem to have an impact by generally causing an 
increase in the flux rate of the marker compounds. This increased flux may be as a result of 
the permeation enhancers influencing the physiochemical properties of harpagoside and 
harpagide to varying degrees as well as direct interaction with the human stratum corneum 
rendering it more permeable. 
7.2.2.4 Human epidermis vs. Synthetic membranes 
 
When comparing the flux values for harpagoside with the human epidermis and synthetic 
membranes, it is observed that the synthetic membranes yielded the highest flux values for 
all three formulations (figure 7.12). The synthetic hydrophilic Tuffryn® membrane yielded the 
highest values for the Gel only and SDS gel formulations and the hydrophobic Sil-Tec® 
membrane for Azone® gel formulation. The Sil-Tec® membrane and human epidermis both 
demonstrated a higher flux value for Azone® gel and a lower SDS gel flux value compared 
to the Tuffryn® membrane. 
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Figure 7.12 Flux values of harpagoside in various gel  
formulations permeating through various membranes. 
 
 
When comparing the flux rates across the stratum corneum and synthetic membrane for 
harpagide as seen in figure 7.13, it was observed that the synthetic membranes have the 
highest permeation rates in all three formulations. Flux across the stratum corneum was 
higher when Azone® and SDS were added to the gel formulation compared to the Gel only 
preparations. This was not the case with the Sil-Tec® and Tuffyrn membranes where the 
former had a decrease in flux upon addition of both enhancers and the latter had a decrease 
in flux with the Azone® formulation. The Gel only flux values of the synthetic membranes 
were at least 5 times higher than that of the human epidermis. 
When comparing the flux of harpagoside and harpagide across the human stratum corneum 
and synthetic membranes, no real similarities could be drawn even though the human and 
hydrophobic membrane displayed some similarity with harpagoside. 
  
-100
0
100
200
300
400
500
600
Hydrophilic Hydrophobic Human skin
µ
g.
cm
-2
 .h
-1
 
Gel
Azone
SDS
 
 
 
 
127 
 
Figure 7.13 Flux values of harpagide in various gel 
 formulations permeating through various membranes. 
 
 
The study by Jantharaprapapa and Stagni (2007) investigating the permeability of 
meloxicam across synthetic and human membranes revealed no relationship between the 
various formulations tested with these membranes. What is noted in their study is that the 
flux values for the synthetic membrane were higher than that of the human skin.  Similarly, 
our study generally indicated that the flux values of harpagoside and harpagide were higher 
in the synthetic membranes. The Jantharaprapapa and Stagni (2007) study also indicated 
that enhancement ratios obtained with permeation enhancers were higher through human 
skin compared to the synthetic membrane. This result was also reflected in this study were 
the presence of Azone® and SDS as enhancers displayed higher enhancement ratios with 
human skin compared to the synthetic membranes. Fang et al., (1999) indicated when 
testing the permeation characteristics of the anti-inflammatory diclofenac sodium, a synthetic 
membrane yielded higher flux values obtained when compared to human skin and rat skin. 
The authors suggested that the large difference in flux values between synthetic and human 
membrane may be due to the higher permeability of the diclofenac through cellulose in the 
hydrophilic membrane related to it being less dense in structure compared to the skin. When 
comparing the flux values of the hydrophilic membrane and the human skin with the 3 
formulations, the differences were statistically significant with the harpagoside. The 
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harpagide also yielded statistical significance except with the Azone® gel formulation. There 
may be other factors contributing to the permeation differences, such as the way the physio-
chemical properties of the marker compounds interacting more actively with the human skin 
compared to the synthetic membranes.  What is also worth considering is that permeation 
across the human skin involves a complex structure such as lipid bilayers whereas 
permeation across a synthetic membrane is a passive diffusional barrier (Barbato et al., 
1998). This would further suggest that physiochemical properties of the marker compounds 
would be more important to consider in active human skin rather than passive synthetic 
membranes as can be seen by the lower overall flux values in the human skin compared to 
that in the synthetic membrane.   
In our study, synthetic membranes were not good indicators of how these compounds would 
permeate human skin but it provided information regarding the permeation profiles of the 
various gel formulations across hydrophilic and hydrophobic membranes. This is useful 
considering the large quantity and variety of compounds such as waxes and sterols present 
in crude plant extracts including Harpagophytum procumbens, which could ultimately affect 
the permeation process. 
When comparing flux values of hydrophilic and hydrophobic membranes with the 3 Gel 
formulations, the flux differences were statistically significant for harpagoside and harpagide 
except for the Azone® Gel formulation for harpagide. This suggests that there are no 
similarities between the 2 synthetic membranes besides generally having higher flux values 
than the human skin. Synthetic membrane permeation systems were developed to predict 
drug permeation across the skin, however, these membrane models merely act as passive 
diffusional barriers (Barbato et al., 1998) and does not take into account the complexity of 
the human epidermis. The permeation profiles of harpagoside and harpagide are dependent 
on the characteristics of the membrane as well as the physiochemical properties of the 
formulation and excipients, which includes permeation enhancers. This observation is similar 
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to Wang et al. (2006) who observed that the formulation components as well as membranes 
contributed to the permeation of penetrants. 
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7.3  Conclusion 
 
Transdermal permeation 
The gel formulation with Azone® as enhancer yielded an enhancement ratio of 14 when 
compared to the Gel only formulation for harpagoside. The SDS Gel formulation did not yield 
an increase in flux for harpagoside.  
When flux values of harpagide which is more hydrophilic than harpagoside was observed it 
can be seen that the gel formulation consisting of Azone® yielded the highest value with an 
enhancement ratio of 8 when compared to the Gel only formulation. The SDS Gel 
formulation yielded an enhancement ratio of 7 with harpagide. 
The formulations producing higher partition co-efficient values for harpagide, namely 
Azone® and SDS formulations resulted in higher flux values compared to the Gel only 
formulation. The same was not observed with harpagoside. 
 
Human epidermis vs. Synthetic membranes 
There were generally no similarities between the synthetic membranes besides having 
higher flux values than human skin. The effect of permeation enhancers in the gel 
formulation did not produce a large increase in the enhancement ratio across the synthetic 
membranes except in the case of harpagoside with Azone® for Sil-Tec® membrane. 
Enhancement ratios achieved with human skin was higher than synthetic membranes. 
Synthetic membranes were not a good indicator of how these compounds would permeate 
human skin but it provided useful information regarding the permeation profiles of the 
various gel formulations across hydrophilic and hydrophobic membranes. However, Sil-Tec® 
membrane could serve as an indicator of possible permeation pattern of human stratum 
corneum for harpagoside. 
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The use of synthetic membranes for preliminary permeation studies with plant compounds is 
important as it provides vital information with respect to the release and availability of active 
compounds from a gel matrix to the surface of a membrane rendering it available for 
permeation across a membrane. This approach therefore, has limited applicability in 
determining the complex processes involved in percutaneous release. It should rather be 
applied as a tool for determining active compound release from topical dosage forms. This 
will be of significance with plant material with its variety of known and unknown compounds, 
which could interact with formulation excipients, which may affect the release of active 
compounds from these formulations. 
 
In the following chapter, post transdermal COX-2 inhibition permeation studies was 
performed to establish whether the crude extract of Harpagophytum procumbens extract has 
maintained its direct COX -2 inhibition activity after permeating through the stratum 
corneum. The Azone® gel formulation was selected as transdermal vehicle to transport 
active ingredients of the crude extract through the human stratum corneum because it 
increased the flux values of harpagoside and harpagide across the stratum corneum. 
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CHAPTER EIGHT Post- Transdermal Cyclooxygenase-2 
    enzyme inhibition. 
 
It was established that the Harpagophytum procumbens extract possessed COX-2 inhibitory 
properties through direct enzyme inhibition. In order to determine whether the crude extract 
maintained its activity after incorporation into a gel formulation followed by in vitro 
transdermal permeation, post permeation COX-2 inhibition experiments were performed. 
This was done after the extract that was formulated into an Azone® gel was exposed to 
human skin in permeation studies. 
8.1  Methods 
 
The interval that yielded the largest quantity of crude extract over the 12 hour permeation 
period in the Franz cell receptor compartment was identified and used to perform the post 
permeation COX-2 inhibition experiments. This was selected to maximize the possibility to 
obtain COX-2 inhibition. The sample Azone® gel contained 300 mg/ml crude extract in the 
donor compartment of the Franz cells. An Azone® gel only formulation excluding the crude 
extract was run in parallel to this sample. 
The sample gel and the Azone® gel only preparation were exposed to the identical 
experimental procedure, which included sample preparation, transdermal permeation and 
solid phase extraction.   
8.1.1  Post-permeation direct COX-2 enzyme inhibition. 
 
For post-permeation COX-2 inhibition studies, the same methodology used in pre-
permeation experiments were implemented (section 5.1.1). These experiments, however, 
did have different reaction mixtures and included solid phase extraction techniques. 
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8.1.1.1 Solid Phase Extraction 
In order to concentrate diluted crude extract collected after transdermal permeation studies 
in the receptor compartment of the Franz cell, solid phase extraction was performed for 
sample enrichment. These enriched samples were added to the COX- reaction mixture to 
determine enzyme inhibition. Solid phase extraction was performed on the sample gel and 
the Azone® only gel.  The same solid phase extraction methods and parameters were used 
as described in section 7.1.1.4.  
8.1.1.2  Reaction mixtures 
 
The following reaction mixtures were used for the post-permeated COX-2 inhibition 
experiments.  
COX-2 reaction mixture (standard reaction) - Arachadonic acid (AA) 100 µM + N,N-
,N’,N’– tetramethyl-p-phenylenediamine (TMPD) 50 µM  + COX-2 enzyme 4 µl (25 units)  + 
buffer solution up to 1000 µl. 
DuP-697 reaction mixture – This is the reference inhibition reaction which consists of 
Arachadonic acid (AA) 100 µM + N,N,N’,N’– tetramethyl-p-phenylenediamine (TMPD) 50 µM  
+COX-2 enzyme 4 µl (25 units)   + DuP-697 50 µl + buffer solution up to 1000 µl. 
Sample Gel reaction mixture (Post-permeation) - Arachadonic acid (AA) 100 µM + N,N-
,N’,N’– tetramethyl-p-phenylenediamine (TMPD) 50 µM  + COX-2 enzyme 4 µl (25 units)   + 
Azone® gel formulation content containing Harpagophytum procumbens crude 
extract 50µl after solid phase + buffer solution up to 1000 µl. 
Gel formulation reaction mixture (Post-permeation) – Arachadonic acid (AA) 100 µM + 
N,N,N’,N’– tetramethyl-p-phenylenediamine (TMPD) 50 µM  + COX-2 enzyme 4 µl (25 units)   
+ Azone® gel formulation content after solid phase extraction + buffer solution up to 
1000 µl. This is the same as the sample gel formulation reaction mixture except it does not 
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contain the crude extract. This was to determine whether the excipients of the formulation 
and solid phase extraction techniques influenced the COX-2 inhibition results. 
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8.2  Results and discussion 
 
The 10 hour Azone® Gel sample yielded the highest quantity of extract when compared to 
the other time intervals in the Franz permeation experiments. This yielded a quantity of 1.9 
mg from the receptor compartment of the Franz cell after solid phase extraction. This 
consisted of the crude extract and possible trace components of the gel formulation. 
Figures 8.1 represents the absorbance versus time graphs for the COX-2 inhibitory activity 
of the Harpagophytum procumbens extract containing the transdermally permeated 10 hour  
Sample Gel (sample Azone® Gel containing Harpagophytum procumbens), permeated 
Azone® Gel only, the reference inhibitor compound (DuP-697) and the standard COX-2 
reaction.  
The standard COX-2 reaction and the permeated Azone Gel only preparation yielded 
identical inhibition curves. This suggests that the Azone Gel formulation excipients did not 
contribute to COX-2 enzyme inhibition. As expected the DuP-697 curve demonstrated the 
greatest COX-2 enzyme inhibition. 
 Figure 8.1 UV absorbance vs. time of post transdermal permeated gel samples. 
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The DuP-697 (0.012 mg) COX-2 inhibitory activity yielded COX-2 inhibition of 83% (figure 
8.2). The post permeation COX-2 inhibitory effect of the sample containing crude 
Harpagophytum procumbens yielded an inhibitory effect of 77%.  
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Figure 8.2 Direct COX-2 enzyme inhibition (post-permeation) 
by Azone® gel only, Sample gel and DuP-697. (n=3; mean ±S.D.) 
    
 
This result is similar to the COX-2 inhibition achieved with the 2mg crude extract (80%), in 
the pre permeation COX-2 inhibition experiments. The Azone® Gel only formulation did not 
display any COX-2 enzyme inhibitory activity (0%), which suggests that the excipients in this 
formulation did not contribute to COX-2 inhibitory activity, and that the inhibitory activity 
observed with the Harpagophytum procumbens Azone® Gel was as a result of the activity of 
the crude extract.  
A study by Ouitas and Heard (2009) evaluated the ability of Harpagophytum Procumbens to 
retain its ability to indirectly inhibit COX-2 inhibition properties after permeation across full 
thickness excised pigskin. The results of the their study demonstrates indirect (COX-2 
expression) COX2 inhibitory effects of Harpagophytum procumbens extract after the 
permeation process but about 25% combined decrease in activity compared to the reference 
extract which did not permeate the pig skin.  
The skin consists of enzymes that may possibly contribute to the breakdown of various 
compounds in the crude extract resulting in decreased inhibitory effects.  The permeation 
process could also have resulted in not all components of the crude extract permeating the 
skin, resulting in lower levels of some components of the extract in the Franz receptor 
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compartment. These factors are suggested by Ouitas and Heard (2009) as being 
contributors to the weaker inhibitory effects of the permeated samples in their study. 
In our study, there was only a 3% reduction in COX2 inhibition between the pre and post 
tested samples. The composition and ratio of the permeated crude drug may have changed 
between the pre and post COX2 samples, however, both samples produced COX-2 
inhibition. This may be due to the possibility that the ratio and composition of the crude 
extract remained unchanged after permeation across the stratum corneum or, the 
composition of the crude extract changed possibly with a lower concentration of the crude 
extract but with higher proportions of permeable compounds such as harpagide, which 
imparts COX-2 inhibition. The possibility of the excipients of the gel formulation contributing 
inhibitory effects can be excluded as figure 7.2 illustrates that  the gel sample did not impart 
any COX-2 inhibition. 
The 77% inhibitory activity achieved by the post permeated crude sample could be 
considered to be mainly attributed to the activity of harpagide rather than harpagoside. This 
suggestion is substantiated in figure 5.6 where the 0.2 mg harpagide compound resulted in 
60% of the COX-2 enzyme where the same concentration of harpagoside only yielded 5% 
activity. The rest of the inhibitory activity could be attributed to the other components that 
permeated through the stratum corneum in the 1.9 mg yield.  
The quantity of Harpagophytum procumbens extract, which permeated at its maximal 
quantity at time interval 10 hours, was more than the quantity required to obtain the IC50 
level, which was 0.1046 mg/ml (table 5.2). 
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8.3  Conclusion 
 
The post-permeated sample gel displayed 77% COX-2 inhibitory properties compared to 
80% obtained in the pre-permeated COX-2 inhibition experiments (Chapter 5). The Azone® 
gel only formulation (without crude extract) did not display any COX-2 enzyme inhibitory 
activity. The experiments proved that Harpagophytum procumbens extract formulated into 
an Azone® gel, maintains its direct COX-2 inhibition properties after it penetrated human 
skin samples. 
Future studies could combine the direct and indirect mechanisms of COX-2 inhibition in 
order to determine the total effect on COX-2 activity by the Harpagophytum procumbens 
extract. 
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CHAPTER NINE  Summary and final conclusions. 
 
The following objectives were set: 
o Develop a standardized extraction method to yield a consistent crude 
Harpagophytum procumbens extract. 
o Perform quality, purity and identity tests by means of Thin layer 
Chromatography and High Pressure Liquid Chromatography  on the 
Harpagophytum procumbens crude extract. 
o Develop a method and experimentally measure the direct COX–2 enzyme 
inhibitory activity of the crude extract of Harpagophytum procumbens, 
harpagoside and harpagide glycosides. 
o Experimentally determine the aqueous solubility, partition co-efficient of 
harpagoside and harpagide components. 
o To formulate the crude extract into a transdermal topical gel preparation. 
o Experimentally perform partition coefficient studies with selected 
permeation enhancers and gel formulation combinations of the 
Harpagophytum procumbens crude extract containing harpagoside and 
harpagide. 
o Experimentally determine the permeation (flux) of harpagoside and 
harpagide compounds from the crude extract in gel formulations across 
synthetic membranes. 
o Experimentally determine the permeation (flux) of harpagoside and 
harpagide compounds from the crude extract in gel formulations across 
the human skin (transdermal). 
o Determine the relationship between the flux values of the synthetic 
membrane and human skin. 
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o Determine the extent to which the gel formulation retained the ability of 
the crude extract to maintain direct COX 2 enzyme inhibition after 
transdermal permeation. 
 
Goals and objectives were achieved by a systematic approach. 
 
Extraction and marker identification 
The Harpagophytum procumbens extract was effectively extracted from the roots of this 
medicinal plant. The harpagoside and harpagide were identified and quantified in the extract 
using various analytical techniques.  
Pre- COX-2 direct inhibition studies 
The direct COX-2 inhibition properties of harpagoside and harpagide compounds as well the 
crude extract was determined.  It was established that harpagide had a greater inhibition on 
the enzyme than harpagoside. The crude extract however had an even larger inhibition 
activity on the enzyme positively indicating polyvalence or synergism of compounds in the 
extract. The IC50 values indicated that the Harpagophytum procumbens crude extract had 
the lowest IC50 concentration when compared to harpagide and harpagoside. 
Partition co-efficient 
The partition coefficient results indicate that harpagoside displayed a higher Log D than 
harpagide.  The addition of permeation enhancers resulted in changes in the partitioning of 
the 2 marker compounds.  
Azone® resulted in the lowest reduction in log D for harpagoside and produced the largest 
increase in log D for harpagide compared to other permeation enhancers tested. 
 
 
 
 
141 
 
Hydroxypropyl cellulose gel produced the highest increase in the log D value for 
harpagoside. All the gel formulations increased the log D values for harpagide with Carbopol 
Ultrez 21® producing the largest increase. 
The hydroxypropyl cellulose gel formulated with SDS and Azone® yielded log D values 
between 0-1 for harpagoside and harpagide. The hydroxypropyl gel was used for all 
permeation experiments. 
Synthetic membrane permeation 
The flux value of harpagide with the Gel only formulation across the hydrophobic Sil-Tec® 
membrane was higher than harpagoside. Conversely the hydrophilic Tuffyrn® membrane 
yielded a higher flux value for harpagoside than harpagide with the same Gel only 
formulation. Incorporation of the crude extract in the Azone® hydroxypropyl cellulose 
formulation resulted in an enhancement ratio (ER) of about 14 for harpagoside with the Sil-
Tec® membrane compared to the gel only preparation. The hydroxypropyl cellulose gel with 
permeation enhancers (Azone® and SDS®) did not result in an increase in permeation of 
harpagide for this membrane. The formulation of Azone® and SDS in the gel resulted in 
decreased flux for harpagoside on the Tuffyrn® membrane. A minimal increase was 
obtained for harpagide in the SDS gel with an ER of 1.4. The permeation results across the 
synthetic membranes suggested that the marker compounds were released from the 
formulations albeit to varying degrees. 
Transdermal permeation experiments 
The gel formulations used in the transdermal permeation experiments were hydroxypropyl 
cellulose with Azone® and SDS. The formulation with Azone® resulted in increased flux to 
produce an ER =14 for harpagoside with no enhancement with SDS obtained. For harpagide 
similar enhancement ratios were obtained with Azone® and SDS, 8 and 7 respectively. 
Overall, formulations containing Azone® obtained the highest permeation across the human 
skin. Enhancement ratios achieved with the human skin was generally higher than that of 
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the synthetic membranes. The permeation profiles of harpagoside and harpagide were 
dependent on the characteristics of the membrane as well as the physiochemical properties 
of the permeation enhancers. 
Post permeation COX-2 inhibition experiments 
The Azone® gel formulation was selected for the post transdermal permeation COX-2 
inhibition studies because it resulted in the highest flux values for harpagoside and 
harpagide. The crude extract retained its COX-2 inhibitory activity after permeation across 
the human skin with 77% inhibition achieved. The inhibitory effects of the pre and post 
transdermal permeated samples were similar.  
 
The Harpagophytum procumbens crude extract was successfully formulated into a topical 
gel consisting of hydroxypropyl cellulose, water, propylene glycol and ethanol with Azone® 
as permeation enhancer. This formulation enhanced the transdermal flux of the harpagide 
and harpagoside and probably other extract components. Further, the preparation 
maintained the ability of the crude extract to effectively permeate the skin without losing its 
COX-2 enzyme inhibition activity. This topical gel preparation has the potential to be utilized 
as an effective natural anti-inflammatory transdermal dosage form. In order for the current 
formulation to be as a suitable pharmaceutical preparation with clinical potential, further 
pharmaceutical, physical and chemical analysis must be performed. 
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ANNEXURES 
Annexure I: 
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Annexure II:  Hydrophobic Membrane 
 
II a. The average cumulative amount of harpagide, which permeated the skin as a function of time to illustrate 
the average flux for the harpagide with the gel only preparation. 
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II b.   The average cumulative amount of harpagoside, which permeated the skin as a function of time to 
illustrate the average flux for the harpagoside with the gel only preparation with the gel only preparation. 
 
0 5 1 0 1 5
0
1 0 0
2 0 0
3 0 0
r
2
=  0 .9 9 7 6
y  =  2 7 .1 1 x  -  8 9 .4 6
T im e  (h )
A
v
e
. 
c
u
m
u
la
ti
v
e
 a
m
o
u
n
t/
a
r
e
a
 (
µ
m
o
l/
c
m
2
)
 
 
 
 
 
 
 
 
 
 
 
 
169 
 
 
II c. The average cumulative amount of harpagide, which permeated the skin as a function of time to illustrate 
the average flux for the harpagide with the SDS-  gel only preparation 
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II d.   The average cumulative amount of harpagoside, which permeated the skin as a function of time to 
illustrate the  average flux for the harpagoside with the SDS- gel preparation. 
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II e. The average cumulative amount of harpagide, which permeated the skin as a function of time to illustrate 
the average flux for the harpagide with the Azone gel only preparation. 
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II f.   The average cumulative amount of harpagoside, which permeated the skin as a function of time to 
illustrate the average flux for the harpagoside with the Azone gel  preparation. 
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Annexure III: Hydrophilic membrane 
 
III a. The average cumulative amount of harpagide, which permeated the skin as a function of time to illustrate 
the average flux for the harpagide with the gel only preparation. 
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III b.   The average cumulative amount of harpagoside, which permeated the skin as a function of time to 
illustrate the average flux for the harpagoside with the gel only preparation. 
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III c. The average cumulative amount of harpagide, which permeated the skin as a function of time to illustrate 
the average flux for the harpagide with the SDS gel  preparation.
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III d. The average cumulative amount of harpagoside, which permeated the skin as a function of time to 
illustrate the average flux for the harpagoside with the SDS  gel  preparation. 
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III e. The average cumulative amount of harpagoside, which permeated the skin as a function of time to illustrate 
the   average flux for the harpagoside with the gel only preparation Hydrophilic Azone Harpagoside 
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Annexure IV: Human Skin 
IV a. The average cumulative amount of harpagide, which permeated the skin as a function of time to illustrate 
the   average flux for the harpagide with the gel only preparation. 
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IV b.  The average cumulative amount of harpagoside, which permeated the skin as a function of time to illustrate 
the    average flux for the harpagoside with the gel only preparation. 
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IV c. The average cumulative amount of harpagide, which permeated the skin as a function of time to illustrate 
the average flux for the harpagide with the SDS gel preparation. 
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IV d. The average cumulative amount of harpagoside, which permeated the skin as a function of time to illustrate 
the average flux for the harpagoside with the SDS gel preparation. 
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IV e The average cumulative amount of harpagide, which permeated the skin as a function of time to illustrate 
the average flux for the harpagide with the Azone  gel preparation. 
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IV f.  The average cumulative amount of harpagoside, which permeated the skin as a function of time to illustrate 
the average flux for the harpagoside with the Azone gel preparation. 
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